S7.9.1.2-14. Olde Nordkamp LR, Postema PG, Knops RE, et al. Implantable cardioverter-defibrillator harm in young patients with inherited arrhythmia syndromes: a systematic review and meta-analysis of inappropriate shocks and complications. Heart Rhythm. 2016;13:443 54. S7.9.1.2-15. Roses-Noguer F, Jarman JW, Clague JR, et al. Outcomes of defi- brillator therapy in catecholaminergic polymorphic ventricular tachycardia. Heart Rhythm. 2014;11:58 66. S7.9.1.2-16. Sy RW, Gollob MH, Klein GJ, et al. Arrhythmia characterization and long-term outcomes in catecholaminergic polymorphic ven- tricular tachycardia. Heart Rhythm. 2011;8:864 71. S7.9.1.2-17. De Ferrari GM, Dusi V, Spazzolini C, et al. Clinical manage- ment of catecholaminergic polymorphic ventricular tachycardia: the role of left cardiac sympathetic denervation. Circulation. 2015;131:2185 93. S7.9.1.2-18. Wilde AA, Bhuiyan ZA, Crotti L, et al. Left cardiac sympathetic denervation for catecholaminergic polymorphic ventricular tachy- cardia. N Engl J Med. 2008;358:2024 9. S7.9.1.2-19. Zhang C, Kutyifa V, Moss AJ, et al. Long-QT syndrome and therapy for attention deficit/hyperactivity disorder. J Cardiovasc Electrophysiol. 2015;26:1039 44. S7.9.1.2-20. Jabbari J, Jabbari R, Nielsen MW, et al. New exome data ques- tion the pathogenicity of genetic variants previously associated with catecholaminergic polymorphic ventricular tachycardia. Circ Cardiovasc Genetics. 2013;6:481 9. S7.9.1.2-21. Crotti L, Johnson CN, Graf E, et al. Calmodulin mutations associated with recurrent cardiac arrest in infants. Circulation. 2013;127:1009 17. S7.9.1.2-22. Makita N, Yagihara N, Crotti L, et al. Novel calmodulin muta- tions associated with congenital arrhythmia susceptibility. Circ Cardiovasc Genet. 2014;7:466 74. S7.9.1.2-23. Marsman RF, Barc J, Beekman L, et al. A mutation in CALM1 encoding calmodulin in familial idiopathic ventricular fibrilla- tion in childhood and adolescence. J Am Coll Cardiol. 2014;63: 259 66. S7.9.1.2-24. Nyegaard M, Overgaard MT, Sondergaard MT, et al. Mutations in calmodulin cause ventricular tachycardia and sudden cardiac death. Am J Hum Genet. 2012;91:703 12. S7.9.1.2-25. Paludan-Muller C, Ahlberg G, Ghouse J, et al.


2012;91:703 12. S7.9.1.2-25. Paludan-Muller C, Ahlberg G, Ghouse J, et al. Integration of 60000 exomes and acmg guidelines question the role of cat- echolaminergic polymorphic ventricular tachycardia-associated variants. Clin Genet. 2017;91:63 72. 7.9.1.3. Brugada Syndrome S7.9.1.3-1. Casado-Arroyo R, Berne P, Rao JY, et al. Long-term trends in newly diagnosed Brugada syndrome: implications for risk stratification. J Am Coll Cardiol. 2016;68:614 23. S7.9.1.3-2. Gehi AK, Duong TD, Metz LD, et al. Risk stratification of indi- viduals with the Brugada electrocardiogram: a meta-analysis. J Cardiovasc Electrophysiol. 2006;17:577 83. S7.9.1.3-3. Hiraoka M, Takagi M, Yokoyama Y, et al. Prognosis and risk strati- fication of young adults with Brugada syndrome. J Electrocardiol. 2013;46:279 83. S7.9.1.3-4. Priori SG, Gasparini M, Napolitano C, et al. Risk stratification in Brugada syndrome: results of the PRELUDE (PRogrammed ELectrical stimUlation preDictive valuE) registry. J Am Coll Cardiol. 2012;59:37 45. S7.9.1.3-5. Probst V, Veltmann C, Eckardt L, et al. Long-term prognosis of patients diagnosed with Brugada syndrome: results from the FINGER Brugada syndrome registry. Circulation. 2010;121: 635 43. S7.9.1.3-6. Sroubek J, Probst V, Mazzanti A, et al. Programmed ventricular stimulation for risk stratification in the Brugada syndrome: a pooled analysis. Circulation. 2016;133:622 30. S7.9.1.3-7. Belhassen B, Rahkovich M, Michowitz Y, et al. Management of Brugada syndrome: thirty-three-year experience using elec- trophysiologically guided therapy with class 1A antiarrhythmic drugs. Circ Arrhythm Electrophysiol. 2015;8:1393 402. S7.9.1.3-8. Brugada J, Pappone C, Berruezo A, et al. Brugada syndrome phe- notype elimination by epicardial substrate ablation. Circ Arrhythm Electrophysiol. 2015;8:1373 81. S7.9.1.3-9. Nademanee K, Veerakul G, Chandanamattha P, et al. Prevention of ventricular fibrillation episodes in Brugada syndrome by cath- eter ablation over the anterior right ventricular outflow tract epi- cardium. Circulation. 2011;123:1270 9. S7.9.1.3-10. Sunsaneewitayakul B, Yao Y, Thamaree S, et al.


2011;123:1270 9. S7.9.1.3-10. Sunsaneewitayakul B, Yao Y, Thamaree S, et al. Endocardial mapping and catheter ablation for ventricular fibrillation preven- tion in Brugada syndrome. J Cardiovasc Electrophysiol. 2012;23 suppl 1:S10 6. S7.9.1.3-11. Zhang P, Tung R, Zhang Z, et al. Characterization of the epicar- dial substrate for catheter ablation of Brugada syndrome. Heart Rhythm. 2016;13:2151 8. CLINICAL STATEMENTS AND GUIDELINES S7.9.1.3-12. Antzelevitch C, Yan GX, Ackerman MJ, et al. J-wave syndromes expert consensus conference report: emerging concepts and gaps in knowledge. Europace. 2017;19:665 94. S7.9.1.3-13. Delise P, Allocca G, Marras E, et al. Risk stratification in individuals with the Brugada type 1 ECG pattern without previous cardiac arrest: usefulness of a combined clinical and electrophysiologic approach. Eur Heart J. 2011;32:169 76. S7.9.1.3-14. Somani R, Krahn AD, Healey JS, et al. Procainamide infusion in the evaluation of unexplained cardiac arrest: from the Cardiac Arrest Survivors with Preserved Ejection Fraction Registry (CASPER). Heart Rhythm. 2014;11:1047 54. S7.9.1.3-15. Kusumoto FM, Bailey KR, Chaouki AS, et al. Systematic review for the 2017 AHA/ACC/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. Circulation. 2018;138:e392 e414. S7.9.1.3-16. Sieira J, Ciconte G, Conte G, et al. Asymptomatic Brugada syn- drome: clinical characterization and long-term prognosis. Circ Arrhythm Electrophysiol. 2015;8:1144 50. S7.9.1.3-17. Sieira J, Conte G, Ciconte G, et al. Prognostic value of pro- grammed electrical stimulation in Brugada syndrome: 20 years experience. Circ Arrhythm Electrophysiol. 2015;8: 777 84. S7.9.1.3-18. Crotti L, Marcou CA, Tester DJ, et al. Spectrum and prevalence of mutations involving BrS1- through BrS12-susceptibility genes in a cohort of unrelated patients referred for Brugada syndrome genetic testing: implications for genetic testing. J Am Coll Cardiol. 2012;60:1410 8.


Spectrum and prevalence of mutations involving BrS1- through BrS12-susceptibility genes in a cohort of unrelated patients referred for Brugada syndrome genetic testing: implications for genetic testing. J Am Coll Cardiol. 2012;60:1410 8. S7.9.1.3-19. Probst V, Wilde AA, Barc J, et al. SCN5A mutations and the role of genetic background in the pathophysiology of Brugada syn- drome. Circ Cardiovasc Genet. 2009;2:552 7. S7.9.1.3-20. Risgaard B, Jabbari R, Refsgaard L, et al. High prevalence of genetic variants previously associated with Brugada syndrome in new exome data. Clinical Genetics. 2013;84:489 95. S7.9.1.3-21. Brugada drugs. Available at: http://www.brugadadrugs.org. Accessed October 6, 2016. S7.9.1.3-22. Postema PG, Wolpert C, Amin AS, et al. Drugs and Brugada syn- drome patients: review of the literature, recommendations, and an up-to-date website (www.brugadadrugs.org). Heart Rhythm. 2009;6:1335 41. S7.9.1.3-23. Andorin A, Behr ER, Denjoy I, et al. Impact of clinical and genetic findings on the management of young patients with Brugada syn- drome. Heart Rhythm. 2016;13:1274 82. S7.9.1.3-24. Priori SG, Wilde AA, Horie M, et al. HRS/EHRA/APHRS expert con- sensus statement on the diagnosis and management of patients with inherited primary arrhythmia syndromes. Heart Rhythm. 2013;10:1932 63. S7.9.1.3-25. McNamara DA, Goldberger JJ, Berendsen MA, et al. Implantable defibrillators versus medical therapy for cardiac channelopathies. Cochrane Database Syst Rev. 2015;CD011168. S7.9.1.3-26. Nademanee K, Veerakul G, Mower M, et al. Defibrillator versus beta-blockers for unexplained death in Thailand (DEBUT): a ran- domized clinical trial. Circulation. 2003;107:2221 6. S7.9.1.3-27. Rodriguez-Manero M, Sacher F, de AC, et al. Monomorphic ventricular tachycardia in patients with Brugada syndrome: a multicenter retrospective study. Heart Rhythm. 2016;13: 669 82. S7.9.1.3-28. Brugada R, Brugada J, Antzelevitch C, et al. Sodium channel blockers identify risk for sudden death in patients with ST-segment elevation and right bundle branch block but structurally normal hearts. Circulation. 2000;101:510 5. S7.9.1.3-29.


Sodium channel blockers identify risk for sudden death in patients with ST-segment elevation and right bundle branch block but structurally normal hearts. Circulation. 2000;101:510 5. S7.9.1.3-29. Shimeno K, Takagi M, Maeda K, et al. Usefulness of multichannel Holter ECG recording in the third intercostal space for detecting type 1 Brugada ECG: comparison with repeated 12-lead ECGs. J Cardiovasc Electrophysiol. 2009;20:1026 31. S7.9.1.3-30. Conte G, Sieira J, Ciconte G, et al. Implantable cardioverter-defi- brillator therapy in Brugada syndrome: a 20-year single-center experience. J Am Coll Cardiol. 2015;65:879 88. S7.9.1.3-31. Kapplinger JD, Tester DJ, Alders M, et al. An international com- pendium of mutations in the SCN5A-encoded cardiac sodium channel in patients referred for Brugada syndrome genetic test- ing. Heart Rhythm. 2010;7:33 46. S7.9.1.3-32. Adler A, Rosso R, Chorin E, et al. Risk stratification in Brugada syn- drome: clinical characteristics, electrocardiographic parameters, and auxiliary testing. Heart Rhythm. 2016;13:299 310. S7.9.1.3-33. Priori SG, Napolitano C, Gasparini M, et al. Natural history of Brugada syndrome: insights for risk stratification and manage- ment. Circulation. 2002;105:1342 7. 7.9.1.4. Early Repolarization J-wave Syndrome S7.9.1.4-1. Rosso R, Kogan E, Belhassen B, et al. J-point elevation in sur- vivors of primary ventricular fibrillation and matched control subjects: incidence and clinical significance. J Am Coll Cardiol. 2008;52:1231 8. S7.9.1.4-2. Adhikarla C, Boga M, Wood AD, et al. Natural history of the electrocardiographic pattern of early repolarization in ambulatory patients. Am J Cardiol. 2011;108:1831 5. S7.9.1.4-3. Haissaguerre M, Sacher F, Nogami A, et al. Characteristics of recurrent ventricular fibrillation associated with inferolateral early repolarization role of drug therapy. J Am Coll Cardiol. 2009;53:612 9. S7.9.1.4-4. Siebermair J, Sinner MF, Beckmann BM, et al. Early repolariza- tion pattern is the strongest predictor of arrhythmia recurrence in patients with idiopathic ventricular fibrillation: results from a single centre long-term follow-up over 20 years. Europace.


Early repolariza- tion pattern is the strongest predictor of arrhythmia recurrence in patients with idiopathic ventricular fibrillation: results from a single centre long-term follow-up over 20 years. Europace. 2016;18:718 25. S7.9.1.4-5. Sinner MF, Porthan K, Noseworthy PA, et al. A meta-analysis of genome-wide association studies of the electrocardio- graphic early repolarization pattern. Heart Rhythm. 2012;9: 1627 34. S7.9.1.4-6. Tikkanen JT, Anttonen O, Junttila MJ, et al. Long-term outcome associated with early repolarization on electrocardiography. N Engl J Med. 2009;361:2529 37. S7.9.1.4-7. Tikkanen JT, Wichmann V, Junttila MJ, et al. Association of early repolarization and sudden cardiac death during an acute coronary event. Circ Arrhythm Electrophysiol. 2012;5:714 8. S7.9.1.4-8. Junttila MJ, Tikkanen JT, Kentta T, et al. Early repolarization as a predictor of arrhythmic and nonarrhythmic cardiac events in middle-aged subjects. Heart Rhythm. 2014;11:1701 6. S7.9.1.4-9. Cheng YJ, Lin XX, Ji CC, et al. Role of early repolarization pat- tern in increasing risk of death. J Am Heart Assoc. 2016;5: e003375. 7.9.1.5. Short QT Syndrome S7.9.1.5-1. Dhutia H, Malhotra A, Parpia S, et al. The prevalence and signifi- cance of a short QT interval in 18825 low-risk individuals includ- ing athletes. Br J Sports Med. 2016;50:124 9. S7.9.1.5-2. Gollob MH, Redpath CJRoberts JD, The short QT syndrome: pro- posed diagnostic criteria. J Am Coll Cardiol. 2011;57:802 1. S7.9.1.5-3. Giustetto C, Schimpf R, Mazzanti A, et al. Long-term follow- up of patients with short QT syndrome. J Am Coll Cardiol. 2011;58:587 95. S7.9.1.5-4. Mazzanti A, Kanthan A, Monteforte N, et al. Novel insight into the natural history of short QT syndrome. J Am Coll Cardiol. 2014;63:1300 8. S7.9.1.5-5. Villafane J, Atallah J, Gollob MH, et al. Long-term follow-up of a pediatric cohort with short QT syndrome. J Am Coll Cardiol. 2013;61:1183 91. S7.9.1.5-6. Giustetto C, Di MF, Wolpert C, et al.


2013;61:1183 91. S7.9.1.5-6. Giustetto C, Di MF, Wolpert C, et al. Short QT syndrome: clini- cal findings and diagnostic-therapeutic implications. Eur Heart J. 2006;27:2440 7. S7.9.1.5-7. Bun SS, Maury P, Giustetto C, et al. Electrical storm in short-QT syndrome successfully treated with isoproterenol. J Cardiovasc Electrophysiol. 2012;23:1028 30. S7.9.1.5-8. Guerrier K, Kwiatkowski D, Czosek RJ, et al. Short QT interval prevalence and clinical outcomes in a pediatric population. Circ Arrhythm Electrophysiol. 2015;8:1460 4. S7.9.1.5-9. Iribarren C, Round AD, Peng JA, et al. Short QT in a cohort of 1.7 million persons: prevalence, correlates, and prognosis. Ann Noninvasive Electrocardiol. 2014;19:490 500. S7.9.1.5-10. Gollob MH, Blier L, Brugada R, et al. Recommendations for the use of genetic testing in the clinical evaluation of inherited car- diac arrhythmias associated with sudden cardiac death: Canadian Cardiovascular Society/Canadian Heart Rhythm Society joint posi- tion paper. Can J Cardiol. 2011;27:232 458. CLINICAL STATEMENTS AND GUIDELINES 8. VA IN THE STRUCTURALLY NORMAL HEART S8-1. Gill JS, Blaszyk K, Ward DE, et al. Verapamil for the suppression of idiopathic ventricular tachycardia of left bundle branch block-like morphology. Am Heart J. 1993;126:1126 33. S8-2. Gill JS, Ward DE, Camm AJ, Comparison of verapamil and diltiazem in the suppression of idiopathic ventricular tachycardia. Pacing Clin Electrophysiol. 1992;15:2122 6. S8-3. Kontos MC, Diercks DB, Ho PM, et al. Treatment and outcomes in patients with myocardial infarction treated with acute beta blocker therapy: results from the American College of Cardiology s NCDR(R). Am Heart J. 2011;161:864 70. S8-4. Levine JH, Massumi A, Scheinman MM, et al. Intravenous amioda- rone for recurrent sustained hypotensive ventricular tachyarrhyth- mias. Intravenous Amiodarone Multicenter Trial Group. J Am Coll Cardiol. 1996;27:67 75. S8-5. Noda T, Shimizu W, Taguchi A, et al.


1996;27:67 75. S8-5. Noda T, Shimizu W, Taguchi A, et al. Malignant entity of idiopathic ventricular fibrillation and polymorphic ventricular tachycardia initi- ated by premature extrasystoles originating from the right ventricu- lar outflow tract. J Am Coll Cardiol. 2005;46:1288 94. S8-6. Viskin S, Idiopathic polymorphic ventricular tachycardia: a benign disease with a touch of bad luck? Korean Circ J. 2017;47: 299 306. S8-7. Viskin S, Rosso R, Rogowski O, et al. The short-coupled variant of right ventricular outflow ventricular tachycardia: a not-so-benign form of benign ventricular tachycardia? J Cardiovasc Electrophysiol. 2005;16:912 6. S8-8. Krittayaphong R, Bhuripanyo K, Punlee K, et al. Effect of ateno- lol on symptomatic ventricular arrhythmia without structural heart disease: a randomized placebo-controlled study. Am Heart J. 2002;144:e10. S8-9. Ling Z, Liu Z, Su L, et al. Radiofrequency ablation versus antiarrhyth- mic medication for treatment of ventricular premature beats from the right ventricular outflow tract: prospective randomized study. Circ Arrhythm Electrophysiol. 2014;7:237 43. S8-10. Hohnloser SH, Meinertz T, Stubbs P, et al. Efficacy and safety of d-sotalol, a pure class III antiarrhythmic compound, in patients with symptomatic complex ventricular ectopy. Results of a multicenter, randomized, double-blind, placebo-controlled dose-finding study. The d-Sotalol PVC Study Group. Circulation. 1995;92:1517 25. S8-11. Badhwar N, Scheinman MM, Idiopathic ventricular tachycardia: diagnosis and management. Curr Probl Cardiol. 2007;32:7 43. S8-12. Connolly SJ, Meta-analysis of antiarrhythmic drug trials. Am J Cardiol. 1999;84:90R 3. S8.1-1. Tada H, Ito S, Naito S, et al. Idiopathic ventricular arrhythmia arising from the mitral annulus: a distinct subgroup of idiopathic ventricu- lar arrhythmias. J Am Coll Cardiol. 2005;45:877 86. 8.1. Outflow Tract and Atrioventricular Annular VA S8.1-2. Yamada T, Litovsky SH, Kay GN, The left ventricular ostium: an ana- tomic concept relevant to idiopathic ventricular arrhythmias. Circ Arrhythm Electrophysiol. 2008;1:396 404. S8.1-3.


Yamada T, Litovsky SH, Kay GN, The left ventricular ostium: an ana- tomic concept relevant to idiopathic ventricular arrhythmias. Circ Arrhythm Electrophysiol. 2008;1:396 404. S8.1-3. Yamada T, Maddox WR, McElderry HT, et al. Radiofrequency cath- eter ablation of idiopathic ventricular arrhythmias originating from intramural foci in the left ventricular outflow tract: efficacy of sequential versus simultaneous unipolar catheter ablation. Circ Arrhythm Electrophysiol. 2015;8:344 52. S8.1-4. Ling Z, Liu Z, Su L, et al. Radiofrequency ablation versus antiarrhyth- mic medication for treatment of ventricular premature beats from the right ventricular outflow tract: prospective randomized study. Circ Arrhythm Electrophysiol. 2014;7:237 43. S8.1-5. Carballeira Pol L, Deyell MW, Frankel DS, et al. Ventricular prema- ture depolarization QRS duration as a new marker of risk for the development of ventricular premature depolarization-induced car- diomyopathy. Heart Rhythm. 2014;11:299 306. S8.1-6. Kamioka M, Mathew S, Lin T, et al. Electrophysiological and electro- cardiographic predictors of ventricular arrhythmias originating from the left ventricular outflow tract within and below the coronary sinus cusps. Clin Res Cardiol. 2015;104:544 54. S8.1-7. Konstantinidou M, Koektuerk B, Wissner E, et al. Catheter ablation of right ventricular outflow tract tachycardia: a simplified remote- controlled approach. Europace. 2011;13:696 700. S8.1-8. Latchamsetty R, Yokokawa M, Morady F, et al. Multicenter out- comes for catheter ablation of idiopathic premature ventricular complexes. JACC Clin Electrophysiol. 2015;1:116 23. S8.1-9. Liao Z, Zhan X, Wu S, et al. Idiopathic ventricular arrhythmias origi- nating from the pulmonary sinus cusp: prevalence, electrocardio- graphic/electrophysiological characteristics, and catheter ablation. J Am Coll Cardiol. 2015;66:2633 44. S8.1-10. Morady F, Kadish AH, DiCarlo L, et al. Long-term results of cath- eter ablation of idiopathic right ventricular tachycardia. Circulation. 1990;82:2093 9. S8.1-11. Ouyang F, Fotuhi P, Ho SY, et al.


1990;82:2093 9. S8.1-11. Ouyang F, Fotuhi P, Ho SY, et al. Repetitive monomorphic ventricular tachycardia originating from the aortic sinus cusp: electrocardio- graphic characterization for guiding catheter ablation. J Am Coll Cardiol. 2002;39:500 8. S8.1-12. Pedersen CT, Kay GN, Kalman J, et al. EHRA/HRS/APHRS expert consensus on ventricular arrhythmias. Heart Rhythm. 2014;11: e166 96. S8.1-13. Tada H, Tadokoro K, Miyaji K, et al. Idiopathic ventricular arrhyth- mias arising from the pulmonary artery: prevalence, character- istics, and topography of the arrhythmia origin. Heart Rhythm. 2008;5:419 26. S8.1-14. Yamada T, McElderry HT, Doppalapudi H, et al. Idiopathic ven- tricular arrhythmias originating from the aortic root prevalence, electrocardiographic and electrophysiologic characteristics, and results of radiofrequency catheter ablation. J Am Coll Cardiol. 2008;52:139 47. S8.1-15. Yamada T, McElderry HT, Doppalapudi H, et al. Idiopathic ventricu- lar arrhythmias originating from the left ventricular summit: ana- tomic concepts relevant to ablation. Circ Arrhythm Electrophysiol. 2010;3:616 23. S8.1-16. Yamada T, McElderry HT, Okada T, et al. Idiopathic left ventricular arrhythmias originating adjacent to the left aortic sinus of valsalva: electrophysiological rationale for the surface electrocardiogram. J Cardiovasc Electrophysiol. 2010;21:170 6. S8.1-17. Mountantonakis SE, Frankel DS, Tschabrunn CM, et al. Ventricular arrhythmias from the coronary venous system: prevalence, map- ping, and ablation. Heart Rhythm. 2015;12:1145 53. S8.1-18. Nagashima K, Choi EK, Lin KY, et al. Ventricular arrhythmias near the distal great cardiac vein: challenging arrhythmia for ablation. Circ Arrhythm Electrophysiol. 2014;7:906 12. S8.1-19. Hai JJ, Chahal AA, Friedman PA, et al. Electrophysiologic charac- teristics of ventricular arrhythmias arising from the aortic mitral continuity-potential role of the conduction system. J Cardiovasc Electrophysiol. 2015;26:158 63. S8.1-20. Tada H, Tadokoro K, Ito S, et al. Idiopathic ventricular arrhythmias originating from the tricuspid annulus: prevalence, electrocardio- graphic characteristics, and results of radiofrequency catheter abla- tion. Heart Rhythm. 2007;4:7 16.


Idiopathic ventricular arrhythmias originating from the tricuspid annulus: prevalence, electrocardio- graphic characteristics, and results of radiofrequency catheter abla- tion. Heart Rhythm. 2007;4:7 16. 8.2 Papillary Muscle VA S8.2-1. Ban JE, Lee HS, Lee DI, et al. Electrophysiological characteristics related to outcome after catheter ablation of idiopathic ventricular arrhythmia originating from the papillary muscle in the left ventricle. Korean Circ J. 2013;43:811 8. S8.2-2. Crawford T, Mueller G, Good E, et al. Ventricular arrhythmias origi- nating from papillary muscles in the right ventricle. Heart Rhythm. 2010;7:725 30. S8.2-3. Doppalapudi H, Yamada T, McElderry HT, et al. Ventricular tachy- cardia originating from the posterior papillary muscle in the left ventricle: a distinct clinical syndrome. Circ Arrhythm Electrophysiol. 2008;1:23 9. S8.2-4. Yamada T, Doppalapudi H, McElderry HT, et al. Electrocardiographic and electrophysiological characteristics in idiopathic ventricular arrhythmias originating from the papillary muscles in the left ven- tricle: relevance for catheter ablation. Circ Arrhythm Electrophysiol. 2010;3:324 31. S8.2-5. Yokokawa M, Good E, Desjardins B, et al. Predictors of successful catheter ablation of ventricular arrhythmias arising from the papil- lary muscles. Heart Rhythm. 2010;7:1654 9. CLINICAL STATEMENTS AND GUIDELINES 8.3. Interfascicular Reentrant VT (Belhassen Tachycardia) S8.3-1. Lin D, Hsia HH, Gerstenfeld EP, et al. Idiopathic fascicular left ven- tricular tachycardia: linear ablation lesion strategy for noninducible or nonsustained tachycardia. Heart Rhythm. 2005;2:934 9. S8.3-2. Liu Y, Fang Z, Yang B, et al. Catheter ablation of fascicular ven- tricular tachycardia: long-term clinical outcomes and mechanisms of recurrence. Circ Arrhythm Electrophysiol. 2015;8:1443 51. S8.3-3. Nogami A, Naito S, Tada H, et al. Demonstration of diastolic and presystolic Purkinje potentials as critical potentials in a macroreentry circuit of verapamil-sensitive idiopathic left ventricular tachycardia. J Am Coll Cardiol. 2000;36:811 23. S8.3-4. Belhassen B, Rotmensch HH, Laniado S, Response of recur- rent sustained ventricular tachycardia to verapamil. Br Heart J.


Belhassen B, Rotmensch HH, Laniado S, Response of recur- rent sustained ventricular tachycardia to verapamil. Br Heart J. 1981;46:679 82. S8.3-5. German LD, Packer DL, Bardy GH, et al. Ventricular tachycardia induced by atrial stimulation in patients without symptomatic car- diac disease. Am J Cardiol. 1983;52:1202 7. S8.3-6. Tsuchiya T, Okumura K, Honda T, et al. Effects of verapamil and lidocaine on two components of the re-entry circuit of verapamil- senstitive idiopathic left ventricular tachycardia. J Am Coll Cardiol. 2001;37:1415 21. S8.3-7. Anderson JH, Tester DJ, Will ML, et al. Whole-exome molecular autopsy after exertion-related sudden unexplained death in the young. Circ Cardiovasc Genet. 2016;9:259 65. S8.3-8. Ohe T, Shimomura K, Aihara N, et al. Idiopathic sustained left ven- tricular tachycardia: clinical and electrophysiologic characteristics. Circulation. 1988;77:560 8. S8.3-9. Snyder C, Bishara J, Darling R, et al. Verapamil-sensitive ventricular tachycardia in an infant. Congenit Heart Dis. 2006;1:124 6. S8.3-10. Wang JD, Fu YC, Jan SL, et al. Verapamil sensitive idiopathic ven- tricular tachycardia in an infant. Jpn Heart J. 2003;44:667 71. 8.4. Idiopathic Polymorphic VT/VF S8.4-1. Anderson JH, Tester DJ, Will ML, et al. Whole-exome molecular autopsy after exertion-related sudden unexplained death in the young. Circ Cardiovasc Genet. 2016;9:259 65. S8.4-2. Dalal A, Czosek RJ, Kovach J, et al. Clinical presentation of pediatric patients at risk for sudden cardiac arrest. J Pediatr. 2016. S8.4-3. Kumar S, Peters S, Thompson T, et al. Familial cardiological and tar- geted genetic evaluation: low yield in sudden unexplained death and high yield in unexplained cardiac arrest syndromes. Heart Rhythm. 2013;10:1653 60. S8.4-4. Linzer M, Pritchett EL, Pontinen M, et al. Incremental diagnostic yield of loop electrocardiographic recorders in unexplained syncope. Am J Cardiol. 1990;66:214 9. S8.4-5. Solomon SD, Zelenkofske S, McMurray JJ, et al.


1990;66:214 9. S8.4-5. Solomon SD, Zelenkofske S, McMurray JJ, et al. Sudden death in patients with myocardial infarction and left ventricular dysfunction, heart failure, or both. N Engl J Med. 2005;352:2581 8. S8.4-6. Tester DJ, Medeiros-Domingo A, Will ML, et al. Unexplained drown- ings and the cardiac channelopathies: a molecular autopsy series. Mayo Clin Proc. 2011;86:941 7. S8.4-7. Tzimas I, Zingraf JC, Bajanowski T, et al. The role of known variants deaths. Int J Legal Med. 2016;1575 9. S8.4-8. Wang D, Shah KR, Um SY, et al. Cardiac channelopathy testing in 274 ethnically diverse sudden unexplained deaths. Forensic Sci Int. 2014;237:90 9. S8.4-9. Conte G, Caputo ML, Regoli F, et al. True idiopathic ventricular fibrillation in out-of-hospital cardiac arrest survivors in the Swiss Canton Ticino: prevalence, clinical features, and long-term follow- up. Europace. 2017;19:259 66. S8.4-10. Frommeyer G, Dechering DG, Kochhauser S, et al. Long-time real- life performance of the subcutaneous ICD in patients with electri- cal heart disease or idiopathic ventricular fibrillation. J Interv Card Electrophysiol. 2016;47:185 8. S8.4-11. Ha ssaguerre M, Shoda M, Jais P, et al. Mapping and ablation of idiopathic ventricular fibrillation. Circulation. 2002;106:962 7. S8.4-12. Knecht S, Sacher F, Wright M, et al. Long-term follow-up of idio- pathic ventricular fibrillation ablation: a multicenter study. J Am Coll Cardiol. 2009;54:522 8. S8.4-13. Leenhardt A, Glaser E, Burguera M, et al. Short-coupled variant of torsade de pointes. A new electrocardiographic entity in the spectrum of idiopathic ventricular tachyarrhythmias. Circulation. 1994;89:206 15. S8.4-14. Ha ssaguerre M, Shah DC, Jais P, et al. Role of Purkinje conduct- ing system in triggering of idiopathic ventricular fibrillation. Lancet. 2002;359:677 8. S8.4-15. Albertella L, Crawford J, Skinner JR, Presentation and outcome of water-related events in children with long QT syndrome. Arch Dis Child. 2011;96:704 7. S8.4-16.


Albertella L, Crawford J, Skinner JR, Presentation and outcome of water-related events in children with long QT syndrome. Arch Dis Child. 2011;96:704 7. S8.4-16. Miyake CY, Motonaga KS, Fischer-Colbrie ME, et al. Risk of cardiac disease and observations on lack of potential predictors by clinical history among children presenting for cardiac evaluation of mid- exertional syncope. Cardiol Young. 2016;26:894 900. S8.4-17. Gula LJ, Klein GJ, Hellkamp AS, et al. Ejection fraction assessment and survival: an analysis of the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT). Am Heart J. 2008;156:1196 200. S8.4-18. Winkel BG, Yuan L, Olesen MS, et al. The role of the sodium current complex in a nonreferred nationwide cohort of sudden infant death syndrome. Heart Rhythm. 2015;12:1241 9. S8.4-19. Noda T, Shimizu W, Taguchi A, et al. Malignant entity of idiopathic ventricular fibrillation and polymorphic ventricular tachycardia initi- ated by premature extrasystoles originating from the right ventricu- lar outflow tract. J Am Coll Cardiol. 2005;46:1288 94. S8.4-20. Sadek MM, Benhayon D, Sureddi R, et al. Idiopathic ventricular arrhythmias originating from the moderator band: electrocardio- graphic characteristics and treatment by catheter ablation. Heart Rhythm. 2015;12:67 75. S8.4-21. Van HH, Zado ES, Haqqani H, et al. Catheter ablation of ventricular fibrillation: importance of left ventricular outflow tract and papillary muscle triggers. Heart Rhythm. 2014;11:566 73. S8.4-22. Viskin S, Belhassen B, Idiopathic ventricular fibrillation. Am Heart J. 1990;120:661 7. 9. PVC-INDUCED CARDIOMYOPATHY S9-1. Ha ssaguerre M, Shah DC, Jais P, et al. Role of Purkinje conduct- ing system in triggering of idiopathic ventricular fibrillation. Lancet. 2002;359:677 8. S9-2. Ha ssaguerre M, Shoda M, Jais P, et al. Mapping and ablation of idiopathic ventricular fibrillation. Circulation. 2002;106:962 7. S9-3. Lee GK, Klarich KW, Grogan M, et al. Premature ventricular contrac- tion-induced cardiomyopathy: a treatable condition. Circ Arrhythm Electrophysiol. 2012;5:229 36. S9-4.


Premature ventricular contrac- tion-induced cardiomyopathy: a treatable condition. Circ Arrhythm Electrophysiol. 2012;5:229 36. S9-4. Singh SN, Fletcher RD, Fisher SG, et al. Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia. Survival Trial of Antiarrhythmic Therapy in Congestive Heart Failure. N Engl J Med. 1995;333:77 82. S9-5. Baman TS, Lange DC, Ilg KJ, et al. Relationship between burden of premature ventricular complexes and left ventricular function. Heart Rhythm. 2010;7:865 9. S9-6. Ban JE, Park HC, Park JS, et al. Electrocardiographic and electrophys- iological characteristics of premature ventricular complexes associ- ated with left ventricular dysfunction in patients without structural heart disease. Europace. 2013;15:735 41. S9-7. Bogun F, Crawford T, Reich S, et al. Radiofrequency ablation of frequent, idiopathic premature ventricular complexes: compari- son with a control group without intervention. Heart Rhythm. 2007;4:863 7. S9-8. Carballeira Pol L, Deyell MW, Frankel DS, et al. Ventricular prema- ture depolarization QRS duration as a new marker of risk for the development of ventricular premature depolarization-induced car- diomyopathy. Heart Rhythm. 2014;11:299 306. S9-9. Del Carpio Munoz F, Syed FF, Noheria A, et al. Characteristics of premature ventricular complexes as correlates of reduced left ven- tricular systolic function: study of the burden, duration, coupling interval, morphology and site of origin of PVCs. J Cardiovasc Electrophysiol. 2011;22:791 8. S9-10. Deyell MW, Park KM, Han Y, et al. Predictors of recovery of left ven- tricular dysfunction after ablation of frequent ventricular premature depolarizations. Heart Rhythm. 2012;9:1465 72. S9-11. Hamon D, Blaye-Felice MS, Bradfield JS, et al. A new combined parameter to predict premature ventricular complexes induced CLINICAL STATEMENTS AND GUIDELINES cardiomyopathy: impact and recognition of epicardial origin. J Cardiovasc Electrophysiol. 2016;27:709 17. S9-12. Hasdemir C, Ulucan C, Yavuzgil O, et al.


2016;27:709 17. S9-12. Hasdemir C, Ulucan C, Yavuzgil O, et al. Tachycardia-induced car- diomyopathy in patients with idiopathic ventricular arrhythmias: the incidence, clinical and electrophysiologic characteristics, and the predictors. J Cardiovasc Electrophysiol. 2011;22:663 8. S9-13. Kanei Y, Friedman M, Ogawa N, et al. Frequent premature ventricu- lar complexes originating from the right ventricular outflow tract are associated with left ventricular dysfunction. Ann Noninvasive Electrocardiol. 2008;13:81 5. S9-14. Kawamura M, Badhwar N, Vedantham V, et al. Coupling interval dispersion and body mass index are independent predictors of idio- pathic premature ventricular complex-induced cardiomyopathy. J Cardiovasc Electrophysiol. 2014;25:756 2. S9-15. Niwano S, Wakisaka Y, Niwano H, et al. Prognostic significance of frequent premature ventricular contractions originating from the ventricular outflow tract in patients with normal left ventricular function. Heart. 2009;95:1230 7. S9-16. Olgun H, Yokokawa M, Baman T, et al. The role of interpolation in PVC-induced cardiomyopathy. Heart Rhythm. 2011;8:1046 9. S9-17. Yokokawa M, Good E, Crawford T, et al. Recovery from left ven- tricular dysfunction after ablation of frequent premature ventricular complexes. Heart Rhythm. 2013;10:172 5. S9-18. Zhong L, Lee YH, Huang XM, et al. Relative efficacy of catheter ablation vs antiarrhythmic drugs in treating premature ventricular contractions: a single-center retrospective study. Heart Rhythm. 2014;11:187 93. S9-19. Deyell MW, Park KM, Han Y, et al. Predictors of recovery of left ven- tricular dysfunction after ablation of frequent ventricular premature depolarizations. Heart Rhythm. 2012;9:1465 72. S9-20. Kubac G, Klinke WP, Grace M, Randomized double blind trial com- paring sotalol and propranolol in chronic ventricular arrhythmia. Can J Cardiol. 1988;4:355 9. 10. VA AND SCD RELATED TO SPECIFIC POPULATIONS S10.1-1. Zipes DP, Link MS, Ackerman MJ, et al.


VA AND SCD RELATED TO SPECIFIC POPULATIONS S10.1-1. Zipes DP, Link MS, Ackerman MJ, et al. Eligibility and disqualifica- tion recommendations for competitive athletes with cardiovascular abnormalities: Task Force 9: arrhythmias and conduction defects: a scientific statement from the American Heart Association and American College of Cardiology. Circulation. 2015;132:e315 28. S10.1-2. Biffi A, Pelliccia A, Verdile L, et al. Long-term clinical significance of frequent and complex ventricular tachyarrhythmias in trained ath- letes. J Am Coll Cardiol. 2002;40:446 52. S10.1-3. Verdile L, Maron BJ, Pelliccia A, et al. Clinical significance of exer- cise-induced ventricular tachyarrhythmias in trained athletes with- out cardiovascular abnormalities. Heart Rhythm. 2015;12:78 85. S10.1-4. Harmon KG, Asif IM, Maleszewski JJ, et al. Incidence, cause, and comparative frequency of sudden cardiac death in national colle- giate athletic association athletes: a decade in review. Circulation. 2015;132:10 9. S10.1-5. Maron BJ, Haas TS, Ahluwalia A, et al. Incidence of cardiovascular sudden deaths in Minnesota high school athletes. Heart Rhythm. 2013;10:374 7. S10.1-6. Harmon KG, Drezner JA, Wilson MG, et al. Incidence of sudden cardiac death in athletes: a state-of-the-art review. Br J Sports Med. 2014;48:1185 92. S10.1-7. Marijon E, Tafflet M, Celermajer DS, et al. Sports-related sudden death in the general population. Circulation. 2011;124:672 81. S10.1-8. Meyer L, Stubbs B, Fahrenbruch C, et al. Incidence, causes, and survival trends from cardiovascular-related sudden cardiac arrest in children and young adults 0 to 35 years of age: a 30-year review. Circulation. 2012;126:1363 72. S10.1-9. Marijon E, Bougouin W, Perier MC, et al. Incidence of sports- related sudden death in France by specific sports and sex. JAMA. 2013;310:642 3. S10.1-10. Anderson JH, Tester DJ, Will ML, et al. Whole-exome molecular autopsy after exertion-related sudden unexplained death in the young. Circ Cardiovasc Genet. 2016;9:259 65. S10.1-11. Bagnall RD, Weintraub RG, Ingles J, et al.


2016;9:259 65. S10.1-11. Bagnall RD, Weintraub RG, Ingles J, et al. A prospective study of sudden cardiac death among children and young adults. N Engl J Med. 2016;374:2441 52. S10.1-12. Semsarian C, Ingles J, Wilde AA, Sudden cardiac death in the young: the molecular autopsy and a practical approach to surviving relatives. Eur Heart J. 2015;36:1290 6. S10.1-13. Maron BJ, Haas TS, Ahluwalia A, et al. Demographics and epide- miology of sudden deaths in young competitive athletes: from the United States national registry. Am J Med. 2016;129:1170 7. S10.1-14. Yankelson L, Sadeh B, Gershovitz L, et al. Life-threatening events during endurance sports: is heat stroke more prevalent than arrhythmic death? J Am Coll Cardiol. 2014;64:463 9. S10.1-15. Maron BJ, Haas TS, Murphy CJ, et al. Incidence and causes of sudden death in US college athletes. J Am Coll Cardiol. 2014;63: 1636 43. S10.1-16. Link MS, Myerburg RJ, Estes NA 3rd. Eligibility and disqualifica- tion recommendations for competitive athletes with cardiovascular abnormalities: Task Force 12: emergency action plans, resuscitation, cardiopulmonary resuscitation, and automated external defibrilla- tors: a scientific statement from the American Heart Association and American College of Cardiology. Circulation. 2015;132:e334 8. S10.1-17. Brothers JA, Frommelt MA, Jaquiss RDB, et al. Expert consensus guideline: anomalous aortic origin of a coronary artery American Association for Thoracic Surgery Clinical Practice Guidelines. J Thorac Cardiovasc Surg. 2017;153:1440 57. S10.1-18. Van Hare GF, Ackerman MJ, Evangelista JA, et al. Eligibility and disqualification recommendations for competitive athletes with car- diovascular abnormalities: Task Force 4: congenital heart disease: a scientific statement from the American Heart Association and American College of Cardiology. Circulation. 2015;132:e281 9. S10.1-19. Ackerman MJ, Zipes DP, Kovacs RJ, et al.


2015;132:e281 9. S10.1-19. Ackerman MJ, Zipes DP, Kovacs RJ, et al. Eligibility and disqualifica- tion recommendations for competitive athletes with cardiovascular abnormalities: Task Force 10: the cardiac channelopathies: a scien- tific statement from the American Heart Association and American College of Cardiology. Circulation. 2015;132:e326 91. S10.1-20. Maron BJ, Udelson JE, Bonow RO, et al. Eligibility and disqualifica- tion recommendations for competitive athletes with cardiovascular abnormalities: Task Force 3: Hypertrophic cardiomyopathy, arrhyth- mogenic right ventricular cardiomyopathy and other cardiomyopa- thies, and myocarditis: a scientific statement from the American Heart Association and American College of Cardiology. Circulation. 2015;132:e273 80. S10.2-1. Seth R, Moss AJ, McNitt S, et al. Long QT syndrome and pregnancy. J Am Coll Cardiol. 2007;49:1092 8. S10.2-2. Jeejeebhoy FM, Zelop CM, Lipman S, et al. Cardiac arrest in preg- nancy: a scientific statement from the American Heart Association. Circulation. 2015;132:1747 73. S10.2-3. Vanden Hoek TL, Morrison LJ, Shuster M, et al. Part 12: cardiac arrest in special situations: 2010 American Heart Association guide- lines for cardiopulmonary resuscitation and emergency cardiovascu- lar care. Circulation. 2010;122 suppl 3:S829 61. S10.2-4. Natale A, Davidson T, Geiger MJ, et al. Implantable cardioverter- defibrillators and pregnancy: a safe combination? Circulation. 1997;96:2808 12. S10.2-5. Colletti PM, Lee KH, Elkayam U, Cardiovascular imaging of the pregnant patient. Am J Roentgenol. 2013;200:515 21. S10.2-6. Khositseth A, Tester DJ, Will ML, et al. Identification of a common genetic substrate underlying postpartum cardiac events in congeni- tal long QT syndrome. Heart Rhythm. 2004;1:60 4. S10.2-7. Rashba EJ, Zareba W, Moss AJ, et al. Influence of pregnancy on the risk for cardiac events in patients with hereditary long QT syndrome. LQTS Investigators. Circulation. 1998;97:451 6. S10.2-8. Heradien MJ, Goosen A, Crotti L, et al. Does pregnancy increase cardiac risk for LQT1 patients with the KCNQ1-A341V mutation? J Am Coll Cardiol.


Does pregnancy increase cardiac risk for LQT1 patients with the KCNQ1-A341V mutation? J Am Coll Cardiol. 2006;48:1410 5. S10.2-9. Davis RL, Eastman D, McPhillips H, et al. Risks of congenital mal- formations and perinatal events among infants exposed to calcium channel and beta-blockers during pregnancy. Pharmacoepidemiol Drug Saf. 2011;20:138 45. S10.2-10. Ruys TP, Maggioni A, Johnson MR, et al. Cardiac medication during pregnancy, data from the ROPAC. Int J Cardiol. 2014;177:124 8. CLINICAL STATEMENTS AND GUIDELINES S10.2-11. Beinder E, Grancay T, Menendez T, et al. Fetal sinus bradycardia and the long QT syndrome. Am J Obstet Gynecol. 2001;185:743 7. S10.2-12. Hofbeck M, Ulmer H, Beinder E, et al. Prenatal findings in patients with prolonged QT interval in the neonatal period. Heart. 1997;77:198 204. S10.2-13. Cuneo BF, Etheridge SP, Horigome H, et al. Arrhythmia phenotype during fetal life suggests long-QT syndrome genotype: risk stratifi- cation of perinatal long-QT syndrome. Circ Arrhythm Electrophysiol. 2013;6:946 51. S10.2-14. Cuneo BF, Strasburger JF, Wakai RT, The natural history of fetal long QT syndrome. J Electrocardiol. 2016;49:807 13. S10.2-15. Damilakis J, Theocharopoulos N, Perisinakis K, et al. Conceptus radiation dose and risk from cardiac catheter ablation procedures. Circulation. 2001;104:893 7. S10.2-16. Duncker D, Haghikia A, Konig T, et al. Risk for ventricular fibrillation in peripartum cardiomyopathy with severely reduced left ventricular function-value of the wearable cardioverter/defibrillator. Eur J Heart Fail. 2014;16:1331 6. 10.3. Older Patients With Comorbidities S10.3-1. Kusumoto FM, Bailey KR, Chaouki AS, et al. Systematic review for the 2017 AHA/ACC/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. Circulation. 2018;138:e392 e414. S10.3-2.


Systematic review for the 2017 AHA/ACC/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. Circulation. 2018;138:e392 e414. S10.3-2. American Geriatrics Society Expert Panel on the Care of Older Adults with M. Guiding principles for the care of older adults with multimorbid- ity: an approach for clinicians. J Am Geriatr Soc. 2012;60:E1 E25. 10.4 Chronic Kidney Disease S10.4-1. Bardy GH, Lee KL, Mark DB, et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med. 2005;352:225 37. S10.4-2. Buxton AE, Lee KL, Fisher JD, et al. A randomized study of the pre- vention of sudden death in patients with coronary artery disease. Multicenter Unsustained Tachycardia Trial Investigators. N Engl J Med. 1999;341:1882 90. S10.4-3. Moss AJ, Hall WJ, Cannom DS, et al. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. Multicenter Automatic Defibrillator Implantation Trial Investigators. N Engl J Med. 1996;335:1933 40. S10.4-4. Moss AJ, Zareba W, Hall WJ, et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejec- tion fraction. N Engl J Med. 2002;346:877 83. S10.4-5. Pun PH, Al-Khatib SM, Han JY, et al. Implantable cardioverter-defi- brillators for primary prevention of sudden cardiac death in CKD: a meta-analysis of patient-level data from 3 randomized trials. Am J Kidney Dis. 2014;64:32 9. S10.4-6. Charytan DM, Patrick AR, Liu J, et al. Trends in the use and outcomes of implantable cardioverter-defibrillators in patients undergoing dialysis in the United States. Am J Kidney Dis. 2011;58:409 17. S10.4-7. Wong MC, Kalman JM, Pedagogos E, et al.


2011;58:409 17. S10.4-7. Wong MC, Kalman JM, Pedagogos E, et al. Bradycardia and asystole is the predominant mechanism of sudden cardiac death in patients with chronic kidney disease. J Am Coll Cardiol. 2015;65:1263 5. S10.4-8. Kusumoto FM, Bailey KR, Chaouki AS, et al. Systematic review for the 2017 AHA/ACC/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. Circulation. 2018;138:e392 e414. S10.4-9. Pun PH, Hellkamp AS, Sanders GD, et al. Primary prevention implantable cardioverter defibrillators in end-stage kidney dis- ease patients on dialysis: a matched cohort study. Nephrol Dial Transplant. 2015;30:829 35. 10.5. Valvular Heart Disease S10.6-1. Nishimura RA, Otto CM, Bonow RO, et al. 2014 AHA/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;129:e521 643. S10.6-2. Genereux P, Stone GW, O Gara PT, et al. Natural history, diagnostic approaches, and therapeutic strategies for patients with asymptom- atic severe aortic stenosis. J Am Coll Cardiol. 2016;67:2263 88. S10.6-3. Avierinos JF, Gersh BJ, Melton LJ 3rd, et al. Natural history of asymptomatic mitral valve prolapse in the community. Circulation. 2002;106:1355 61. S10.6-4. Grigioni F, Enriquez-Sarano M, Ling LH, et al. Sudden death in mitral regurgitation due to flail leaflet. J Am Coll Cardiol. 1999;34:2078 85. S10.6-5. Nordhues BD, Siontis KC, Scott CG, et al. Bileaflet mitral valve pro- lapse and risk of ventricular dysrhythmias and death. J Cardiovasc Electrophysiol. 2016;27:463 8. S10.6-6. Basso C, Perazzolo MM, Rizzo S, et al. Arrhythmic mitral valve pro- lapse and sudden cardiac death. Circulation. 2015;132:556 66. S10.6-7. Sriram CS, Syed FF, Ferguson ME, et al.


2015;132:556 66. S10.6-7. Sriram CS, Syed FF, Ferguson ME, et al. Malignant bileaflet mitral valve prolapse syndrome in patients with otherwise idiopathic out- of-hospital cardiac arrest. J Am Coll Cardiol. 2013;62:222 30. S10.6-8. Albert CM, Chae CU, Grodstein F, et al. Prospective study of sud- den cardiac death among women in the United States. Circulation. 2003;107:2096 101. S10.6-9. Kannel WB, Wilson PW, D Agostino RB, et al. Sudden coronary death in women. Am Heart J. 1998;136:205 12. S10.6-10. Bogle BM, Ning H, Mehrotra S, et al. Lifetime risk for sudden cardiac death in the community. J Am Heart Assoc. 2016;5:e002398. S10.6-11. Kim C, Fahrenbruch CE, Cobb LA, et al. Out-of-hospital cardiac arrest in men and women. Circulation. 2001;104:2699 703. S10.6-12. Teodorescu C, Reinier K, Uy-Evanado A, et al. Survival advantage from ventricular fibrillation and pulseless electrical activity in women compared to men: the Oregon Sudden Unexpected Death Study. J Interv Card Electrophysiol. 2012;34:219 25. S10.6-13. Wissenberg M, Hansen CM, Folke F, et al. Survival after out-of- hospital cardiac arrest in relation to sex: a nationwide registry-based study. Resuscitation. 2014;85:1212 8. S10.6-14. Bray JE, Stub D, Bernard S, et al. Exploring gender differences and the oestrogen effect in an Australian out-of-hospital cardiac arrest population. Resuscitation. 2013;84:957 63. S10.6-15. Ng YY, Wah W, Liu N, et al. Associations between gender and car- diac arrest outcomes in Pan-Asian out-of-hospital cardiac arrest patients. Resuscitation. 2016;102:116 21. S10.6-16. Hagihara A, Onozuka D, Hasegawa M, et al. Resuscitation out- comes of reproductive-age females who experienced out-of-hospi- tal cardiac arrest. Eur Heart J Acute Cardiovasc Care. 2017;6:121 9. S10.6-17. Safdar B, Stolz U, Stiell IG, et al. Differential survival for men and women from out-of-hospital cardiac arrest varies by age: results from the OPALS study. Acad Emerg Med. 2014;21:1503 11. S10.6-18.


Differential survival for men and women from out-of-hospital cardiac arrest varies by age: results from the OPALS study. Acad Emerg Med. 2014;21:1503 11. S10.6-18. Albert CM, McGovern BA, Newell JB, et al. Sex differences in car- diac arrest survivors. Circulation. 1996;93:1170 6. S10.6-19. Chugh SS, Uy-Evanado A, Teodorescu C, et al. Women have a lower prevalence of structural heart disease as a precursor to sudden cardiac arrest: The Ore-SUDS (Oregon Sudden Unexpected Death Study). J Am Coll Cardiol. 2009;54:2006 11. S10.6-20. Kim MJ, Shin SD, McClellan WM, et al. Neurological prognostica- tion by gender in out-of-hospital cardiac arrest patients receiving hypothermia treatment. Resuscitation. 2014;85:1732 8. S10.6-21. Marijon E, Bougouin W, Perier MC, et al. Incidence of sports- related sudden death in France by specific sports and sex. JAMA. 2013;310:642 3. S10.6-22. Makkar RR, Fromm BS, Steinman RT, et al. Female gender as a risk factor for torsades de pointes associated with cardiovascular drugs. JAMA. 1993;270:2590 7. S10.6-23. Higgins AY, Waks JWJosephson ME, Influence of gender on the tolerability, safety, and efficacy of quinidine used for treatment of supraventricular and ventricular arrhythmias. Am J Cardiol. 2015;116:1845 51. S10.6-24. Tanaka Y, Tada H, Ito S, et al. Gender and age differences in candi- dates for radiofrequency catheter ablation of idiopathic ventricular arrhythmias. Circ J. 2011;75:1585 91. 10.7. Medication-Induced Arrhythmias S10.7-1. Antman EM, Wenger TL, Butler VP Jr, et al. Treatment of 150 cases of life-threatening digitalis intoxication with digoxin-specific Fab CLINICAL STATEMENTS AND GUIDELINES antibody fragments. Final report of a multicenter study. Circulation. 1990;81:1744 52. S10.7-2. Chan BS, Buckley NA, Digoxin-specific antibody fragments in the treatment of digoxin toxicity. Clin Toxicol. 2014;52:824 36. S10.7-3. Keren A, Tzivoni D, Gavish D, et al. Etiology, warning signs and therapy of torsade de pointes. A study of 10 patients. Circulation. 1981;64:1167 74. S10.7-4.


Etiology, warning signs and therapy of torsade de pointes. A study of 10 patients. Circulation. 1981;64:1167 74. S10.7-4. Tzivoni D, Banai S, Schuger C, et al. Treatment of torsade de pointes with magnesium sulfate. Circulation. 1988;77:392 7. S10.7-5. Kannankeril P, Roden DM, Darbar D, Drug-induced long QT syn- drome. Pharmacol Rev. 2010;62:760 81. S10.7-6. Choy AM, Lang CC, Chomsky DM, et al. Normalization of acquired QT prolongation in humans by intravenous potassium. Circulation. 1997;96:2149 54. S10.7-7. Yang T, Roden DM, Extracellular potassium modulation of drug block of IKr. Implications for torsade de pointes and reverse use- dependence. Circulation. 1996;93:407 11. S10.7-8. Hellestrand KJ, Burnett PJ, Milne JR, et al. Effect of the antiarrhyth- mic agent flecainide acetate on acute and chronic pacing thresh- olds. Pacing Clin Electrophysiol. 1983;6:892 9. S10.7-9. Echt DS, Black JN, Barbey JT, et al. Evaluation of antiarrhyth- mic drugs on defibrillation energy requirements in dogs. Sodium channel block and action potential prolongation. Circulation. 1989;79:1106 17. S10.7-10. Schwartz PJ, Woosley RL, Predicting the unpredictable: drug- induced QT prolongation and torsades de pointes. J Am Coll Cardiol. 2016;67:1639 50. S10.7-11. Hauptman PJ, Kelly RA, Digitalis. Circulation. 1999;99:1265 70. S10.7-12. Kelly RA, Smith TW, Recognition and management of digitalis toxic- ity. Am J Cardiol. 1992;69:108G 18G. S10.7-13. Osmonov D, Erdinler I, Ozcan KS, et al. Management of patients with drug-induced atrioventricular block. Pacing Clin Electrophysiol. 2012;35:804 10. S10.7-14. Zipes DP, Camm AJ, Borggrefe M, et al. ACC/AHA/ESC 2006 guide- lines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines. Circulation. 2006;114:e385 484. S10.7-15. Behr ER, Ritchie MD, Tanaka T, et al.


2006;114:e385 484. S10.7-15. Behr ER, Ritchie MD, Tanaka T, et al. Genome wide analysis of drug- induced torsades de pointes: lack of common variants with large effect sizes. PloS One. 2013;8:e78511. S10.7-16. Kaab S, Crawford DC, Sinner MF, et al. A large candidate gene sur- vey identifies the KCNE1 D85N polymorphism as a possible modu- lator of drug-induced torsades de pointes. Circ Cardiovasc Genet. 2012;5:91 9. S10.7-17. Strauss DG, Vicente J, Johannesen L, et al. A common genetic variant risk score is associated with drug-induced QT prolon- gation and torsade de pointes risk: a pilot study. Circulation. 2017;135:1300 10. S10.7-18. Yang P, Kanki H, Drolet B, et al. Allelic variants in long-QT dis- ease genes in patients with drug-associated torsades de pointes. Circulation. 2002;105:1943 8. S10.7-19. Weeke P, Mosley JD, Hanna D, et al. Exome sequencing implicates an increased burden of rare potassium channel variants in the risk of drug-induced long QT interval syndrome. J Am Coll Cardiol. 2014;63:1430 7. S10.7-20. Echt DS, Liebson PR, Mitchell LB, et al. Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. N Engl J Med. 1991;324:781 8. S10.7-21. Chamberlain DA, Jewitt DE, Julian DG, et al. Oral mexiletine in high- risk patients after myocardial infarction. Lancet. 1980;2:1324 7. S10.7-22. UK Rythmodan Multicentre Study Group Oral disopyramide after admission to hospital with suspected acute myocardial infarc- tion. U. K. Rythmodan Multicentre Study Group. Postgrad Med J. 1984;60:98 107. S10.7-23. Crijns HJ, Van Gelder IC, Lie KI, Supraventricular tachycardia mim- icking ventricular tachycardia during flecainide treatment. Am J Cardiol. 1988;62:1303 6. S10.7-24. Alings M, Wilde A, Brugada syndrome: clinical data and suggested pathophysiological mechanism. Circulation. 1999;99:666 73. S10.7-25. Konigstein M, Rosso R, Topaz G, et al. Drug-induced Brugada syndrome: clinical characteristics and risk factors. Heart Rhythm. 2016;13:1083 7. S10.7-26.


Drug-induced Brugada syndrome: clinical characteristics and risk factors. Heart Rhythm. 2016;13:1083 7. S10.7-26. Tada H, Sticherling C, Oral H, et al. Brugada syndrome mimicked by tricyclic antidepressant overdose. J Cardiovasc Electrophysiol. 2001;12:275. S10.7-27. Littmann L, Monroe MH, Svenson RH, Brugada-type electro- cardiographic pattern induced by cocaine. Mayo Clin Proc. 2000;75:845 9. S10.7-28. Brugada drugs. Available at: http://www.brugadadrugs.org. Accessed October 6, 2016. S10.7-29. Bajaj AK, Woosley RL, Roden DM, Acute electrophysiologic effects of sodium administration in dogs treated with O-desmethyl encainide. Circulation. 1989;80:994 1002. S10.7-30. Myerburg RJ, Kessler KM, Cox MM, et al. Reversal of proarrhythmic effects of flecainide acetate and encainide hydrochloride by pro- pranolol. Circulation. 1989;80:1571 9. S10.7-31. Brumfield E, Bernard KR, Kabrhel C, Life-threatening flecainide overdose treated with intralipid and extracorporeal membrane oxy- genation. Am J Emerg Med. 2015;33:1840 5. S10.7-32. Credible meds. Available at: http://www.crediblemeds.org. Accessed December 26, 2016. 10.8. Adult Congenital Heart Disease S10.8-1. Diller GP, Kempny A, Liodakis E, et al. Left ventricular longitu- dinal function predicts life-threatening ventricular arrhythmia and death in adults with repaired tetralogy of fallot. Circulation. 2012;125:2440 6. S10.8-2. Gatzoulis MA, Till JA, Somerville J, et al. Mechanoelectrical interac- tion in tetralogy of Fallot. QRS prolongation relates to right ventricu- lar size and predicts malignant ventricular arrhythmias and sudden death. Circulation. 1995;92:231 7. S10.8-3. Harrison DA, Harris L, Siu SC, et al. Sustained ventricular tachycardia in adult patients late after repair of tetralogy of Fallot. J Am Coll Cardiol. 1997;30:1368 73. S10.8-4. Knauth AL, Gauvreau K, Powell AJ, et al. Ventricular size and func- tion assessed by cardiac MRI predict major adverse clinical outcomes late after tetralogy of Fallot repair. Heart. 2008;94:211 6. S10.8-5. Koyak Z, de Groot JR, Bouma BJ, et al. Sudden cardiac death in adult congenital heart disease: can the unpredictable be foreseen? Europace. 2017;19:401 6. S10.8-6.


Sudden cardiac death in adult congenital heart disease: can the unpredictable be foreseen? Europace. 2017;19:401 6. S10.8-6. Koyak Z, Harris L, de Groot JR, et al. Sudden cardiac death in adult congenital heart disease. Circulation. 2012;126:1944 54. S10.8-7. Adamson L, Vohra HA, Haw MP, Does pulmonary valve replacement post repair of tetralogy of Fallot improve right ventricular function? Interact Cardiovasc Thorac Surg. 2009;9:520 7. S10.8-8. Deal BJ, Scagliotti D, Miller SM, et al. Electrophysiologic drug testing in symptomatic ventricular arrhythmias after repair of tetralogy of Fallot. Am J Cardiol. 1987;59:1380 5. S10.8-9. Khairy P, Van Hare GF, Balaji S, et al. PACES/HRS Expert consensus statement on the recognition and management of arrhythmias in adult congenital heart disease: developed in partnership between the Pediatric and Congenital Electrophysiology Society (PACES) and the Heart Rhythm Society (HRS). Heart Rhythm. 2014;11:e102 65. S10.8-10. Sabate Rotes A, Connolly HM, Warnes CA, et al. Ventricular arrhyth- mia risk stratification in patients with tetralogy of Fallot at the time of pulmonary valve replacement. Circ Arrhythm Electrophysiol. 2015;8:110 6. S10.8-11. Therrien J, Provost Y, Merchant N, et al. Optimal timing for pulmo- nary valve replacement in adults after tetralogy of Fallot repair. Am J Cardiol. 2005;95:779 82. S10.8-12. Therrien J, Siu SC, Harris L, et al. Impact of pulmonary valve replace- ment on arrhythmia propensity late after repair of tetralogy of Fallot. Circulation. 2001;103:2489 94. S10.8-13. Kella DK, Merchant FM, Veledar E, et al. Lesion-specific dif- ferences for implantable cardioverter defibrillator therapies in adults with congenital heart disease. Pacing Clin Electrophysiol. 2014;37:1492 8. S10.8-14. Koyak Z, de Groot JR, Van Gelder IC, et al. Implantable cardioverter defibrillator therapy in adults with congenital heart disease: who is at risk of shocks? Circ Arrhythm Electrophysiol. 2012;5:101 10. S10.8-15. Santharam S, Hudsmith L, Thorne S, et al.


2012;5:101 10. S10.8-15. Santharam S, Hudsmith L, Thorne S, et al. Long-term follow- up of implantable cardioverter-defibrillators in adult congeni- tal heart disease patients: indications and outcomes. Europace. 2017;19:407 13. CLINICAL STATEMENTS AND GUIDELINES S10.8-16. Vehmeijer JT, Brouwer TF, Limpens J, et al. Implantable cardioverter- defibrillators in adults with congenital heart disease: a systematic review and meta-analysis. Eur Heart J. 2016;37:1439 48. S10.8-17. Yap SC, Roos-Hesselink JW, Hoendermis ES, et al. Outcome of implantable cardioverter defibrillators in adults with congenital heart disease: a multi-centre study. Eur Heart J. 2007;28:1854 61. S10.8-18. Chandar JS, Wolff GS, Garson A, Jr, et al. Ventricular arrhythmias in postoperative tetralogy of Fallot. Am J Cardiol. 1990;65:655 61. S10.8-19. Khairy P, Landzberg MJ, Gatzoulis MA, et al. Value of programmed ventricular stimulation after tetralogy of fallot repair: a multicenter study. Circulation. 2004;109:1994 2000. S10.8-20. Khairy P, Harris L, Landzberg MJ, et al. Implantable cardioverter- defibrillators in tetralogy of Fallot. Circulation. 2008;117:363 70. S10.8-21. Kapel GF, Reichlin T, Wijnmaalen AP, et al. Re-entry using anatomi- cally determined isthmuses: a curable ventricular tachycardia in repaired congenital heart disease. Circ Arrhythm Electrophysiol. 2015;8:102 9. S10.8-22. Kapel GF, Reichlin T, Wijnmaalen AP, et al. Left-sided ablation of ventricular tachycardia in adults with repaired tetralogy of Fallot: a case series. Circ Arrhythm Electrophysiol. 2014;7:889 97. S10.8-23. Kapel GF, Sacher F, Dekkers OM, et al. Arrhythmogenic anatomi- cal isthmuses identified by electroanatomical mapping are the sub- strate for ventricular tachycardia in repaired tetralogy of Fallot. Eur Heart J. 2017;38:268 76. S10.8-24. van Zyl M, Kapa S, Padmanabhan D, et al. Mechanism and out- comes of catheter ablation for ventricular tachycardia in adults with repaired congenital heart disease. Heart Rhythm. 2016;13:1449 54. S10.8-25. Zeppenfeld K, Schalij MJ, Bartelings MM, et al.


2016;13:1449 54. S10.8-25. Zeppenfeld K, Schalij MJ, Bartelings MM, et al. Catheter ablation of ventricular tachycardia after repair of congenital heart disease: elec- troanatomic identification of the critical right ventricular isthmus. Circulation. 2007;116:2241 52. S10.8-26. Khairy P, Harris L, Landzberg MJ, et al. Sudden death and defibrilla- tors in transposition of the great arteries with intra-atrial baffles: a multicenter study. Circ Arrhythm Electrophysiol. 2008;1:250 7. S10.8-27. Engelings CC, Helm PC, Abdul-Khaliq H, et al. Cause of death in adults with congenital heart disease - an analysis of the German National Register for Congenital Heart Defects. Int J Cardiol. 2016;211:31 6. S10.8-28. Gallego P, Gonzalez AE, Sanchez-Recalde A, et al. Incidence and predictors of sudden cardiac arrest in adults with congenital heart defects repaired before adult life. Am J Cardiol. 2012;110:109 17. S10.8-29. Tutarel O, Kempny A, Alonso-Gonzalez R, et al. Congenital heart disease beyond the age of 60: emergence of a new population with high resource utilization, high morbidity, and high mortality. Eur Heart J. 2014;35:725 32. S10.8-30. Fish FA, Gillette PC, Benson DW Jr, Proarrhythmia, cardiac arrest and death in young patients receiving encainide and flecainide. The Pediatric Electrophysiology Group. J Am Coll Cardiol. 1991;18:356 65. S10.8-31. Stan MN, Sathananthan M, Warnes C, et al. Amiodarone-induced thyrotoxicosis in adults with congenital heart disease-clinical pre- sentation and response to therapy. Endocr Pract. 2014;21:33 40. S10.8-32. Thorne SA, Barnes I, Cullinan P, et al. Amiodarone-associated thy- roid dysfunction: risk factors in adults with congenital heart disease. Circulation. 1999;100:149 54. S10.8-33. Garson A Jr, Porter CB, Gillette PC, et al. Induction of ventricular tachycardia during electrophysiologic study after repair of tetralogy of Fallot. J Am Coll Cardiol. 1983;1:1493 502. S10.8-34. Khairy P, Aboulhosn J, Gurvitz MZ, et al. Arrhythmia burden in adults with surgically repaired tetralogy of Fallot: a multi-institu- tional study.


Arrhythmia burden in adults with surgically repaired tetralogy of Fallot: a multi-institu- tional study. Circulation. 2010;122:868 75. S10.8-35. Tsai SF, Chan DP, Ro PS, et al. Rate of inducible ventricular arrhythmia in adults with congenital heart disease. Am J Cardiol. 2010;106:730 6. S10.8-36. Valente AM, Gauvreau K, Assenza GE, et al. Contemporary predic- tors of death and sustained ventricular tachycardia in patients with repaired tetralogy of Fallot enrolled in the INDICATOR cohort. Heart. 2014;100:247 53. S10.8-37. Sakamoto T, Nagashima M, Hiramatsu T, et al. Fontan circulation over 30 years. What should we learn from those patients? Asian Cardiovasc Thorac Ann. 2016;24:765 71. S10.8-38. Harrild DM, Berul CI, Cecchin F, et al. Pulmonary valve replacement in tetralogy of Fallot: impact on survival and ventricular tachycardia. Circulation. 2009;119:445 51. S10.8-39. Berul CI, Van Hare GF, Kertesz NJ, et al. Results of a multicenter retrospective implantable cardioverter-defibrillator registry of pedi- atric and congenital heart disease patients. J Am Coll Cardiol. 2008;51:1685 91. S10.8-40. Khanna AD, Warnes CA, Phillips SD, et al. Single-center experience with implantable cardioverter-defibrillators in adults with complex congenital heart disease. Am J Cardiol. 2011;108:729 34. S10.8-41. Moore JP, Mondesert B, Lloyd MS, et al. Clinical experience with the subcutaneous implantable cardioverter-defibrillator in adults with congenital heart disease. Circ Arrhythm Electrophysiol. 2016;9:e004338. S10.8-42. Okamura H, McLeod CJ, DeSimone CV, et al. Right parasternal lead placement increases eligibility for subcutaneous implantable cardio- verter defibrillator therapy in adults with congenital heart disease. Circ J. 2016;80:1328 35. S10.8-43. Witte KK, Pepper CB, Cowan JC, et al. Implantable cardioverter- defibrillator therapy in adult patients with tetralogy of Fallot. Europace. 2008;10:926 30. S10.8-44. Raissadati A, Nieminen H, Haukka J, et al. Late causes of death after pediatric cardiac surgery: a 60-year population-based study. J Am Coll Cardiol. 2016;68:487 98. S10.8-45.


Late causes of death after pediatric cardiac surgery: a 60-year population-based study. J Am Coll Cardiol. 2016;68:487 98. S10.8-45. Diller GP, Kempny A, Alonso-Gonzalez R, et al. Survival prospects and circumstances of death in contemporary adult congenital heart disease patients under follow-up at a large tertiary centre. Circulation. 2015;132:2118 25. S10.8-46. Nieminen HP, Jokinen EV, Sairanen HI, Causes of late deaths after pediatric cardiac surgery: a population-based study. J Am Coll Cardiol. 2007;50:1263 71. S10.8-47. Zomer AC, Vaartjes I, Uiterwaal CS, et al. Circumstances of death in adult congenital heart disease. Int J Cardiol. 2012;154:168 72. S10.8-48. Lange R, Horer J, Kostolny M, et al. Presence of a ventricular septal defect and the Mustard operation are risk factors for late mortality after the atrial switch operation: thirty years of follow-up in 417 patients at a single center. Circulation. 2006;114:1905 13. S10.8-49. Lubiszewska B, Gosiewska E, Hoffman P, et al. Myocardial perfusion and function of the systemic right ventricle in patients after atrial switch procedure for complete transposition: long-term follow-up. J Am Coll Cardiol. 2000;36:1365 70. S10.8-50. Millane T, Bernard EJ, Jaeggi E, et al. Role of ischemia and infarction in late right ventricular dysfunction after atrial repair of transposi- tion of the great arteries. J Am Coll Cardiol. 2000;35:1661 8. S10.8-51. Schwerzmann M, Salehian O, Harris L, et al. Ventricular arrhythmias and sudden death in adults after a Mustard operation for transposi- tion of the great arteries. Eur Heart J. 2009;30:1873 9. S10.8-52. Buber J, Ackley TJ, Daniels CJ, et al. Outcomes following the implantation of cardioverter-defibrillator for primary prevention in transposition of the great arteries after intra-atrial baffle repair: a single-centre experience. Europace. 2016;18:1016 22. S10.8-53. Backhoff D, Kerst G, Peters A, et al.


2016;18:1016 22. S10.8-53. Backhoff D, Kerst G, Peters A, et al. Internal cardioverter defibril- lator indications and therapies after atrial baffle procedure for d-transposition of the great arteries: a multicenter analysis. Pacing Clin Electrophysiol. 2016;39:1070 6. S10.8-54. Oechslin EN, Harrison DA, Connelly MS, et al. Mode of death in adults with congenital heart disease. Am J Cardiol. 2000;86:1111 6. S10.8-55. Verheugt CL, Uiterwaal CS, van der Velde ET, et al. Mortality in adult congenital heart disease. Eur Heart J. 2010;31:1220 9. S10.8-56. Silka MJ, Hardy BG, Menashe VD, et al. A population-based pro- spective evaluation of risk of sudden cardiac death after opera- tion for common congenital heart defects. J Am Coll Cardiol. 1998;32:245 51. S10.8-57. Abou Hassan OK, Fahed AC, Batrawi M, et al. NKX2-5 mutations in an inbred consanguineous population: genetic and phenotypic diversity. Sci Rep. 2015;5:8848. S10.8-58. El Malti R, Liu H, Doray B, et al. A systematic variant screening in familial cases of congenital heart defects demonstrates the use- fulness of molecular genetics in this field. Eur J Human Genet. 2016;24:228 36. S10.8-59. Ellesoe SG, Johansen MM, Bjerre JV, et al. Familial atrial septal defect and sudden cardiac death: identification of a novel NKX2-5 mutation and a review of the literature. Congenit Heart Dis. 2016;11:283 90. S10.8-60. Cuypers JA, Opic P, Menting ME, et al. The unnatural history of an atrial septal defect: longitudinal 35 year follow up after surgical closure at young age. Heart. 2013;99:1346 52. CLINICAL STATEMENTS AND GUIDELINES S10.8-61. Kuijpers JM, van der Bom T, van Riel AC, et al. Secundum atrial septal defect is associated with reduced survival in adult men. Eur Heart J. 2015;36:2079 86. S10.8-62. Verheugt CL, Uiterwaal CS, Grobbee DE, et al. Long-term progno- sis of congenital heart defects: a systematic review. Int J Cardiol. 2008;131:25 32. S10.8-63.


Long-term progno- sis of congenital heart defects: a systematic review. Int J Cardiol. 2008;131:25 32. S10.8-63. Engelfriet P, Boersma E, Oechslin E, et al. The spectrum of adult congenital heart disease in Europe: morbidity and mortality in a 5 year follow-up period. The Euro Heart Survey on adult congenital heart disease. Eur Heart J. 2005;26:2325 33. S10.8-64. Arya S, Kovach J, Singh H, et al. Arrhythmias and sudden death among older children and young adults following tetralogy of Fallot repair in the current era: are previously reported risk factors still applicable? Congenit Heart Dis. 2014;9:407 14. S10.8-65. Wu MH, Lu CW, Chen HC, et al. Arrhythmic burdens in patients with tetralogy of Fallot: a national database study. Heart Rhythm. 2015;12:604 9. S10.8-66. Baraona F, Valente AM, Porayette P, et al. Coronary arteries in child- hood heart disease: implications for management of young adults. J Clin Exp Cardiolog. suppl 8 2012 006. S10.8-67. Naimo PS, Fricke TA, Yong MS, et al. Outcomes of truncus arteriosus repair in children: 35 years of experience from a single institution. Semin Thorac Cardiovasc Surg. 2016;28:500 11. S10.8-68. Pundi KN, Pundi KN, Johnson JN, et al. Sudden cardiac death and late arrhythmias after the Fontan operation. Congenit Heart Dis. 2017;12:17 23. 11. DEFIBRILLATORS OTHER THAN TRANSVENOUS ICDS 11.1. Subcutaneous Implantable Cardioverter-Defibrillator S11.1-1. Bardy GH, Smith WM, Hood MA, et al. An entirely subcuta- neous implantable cardioverter-defibrillator. N Engl J Med. 2010;363:36 44. S11.1-2. Weiss R, Knight BP, Gold MR, et al. Safety and efficacy of a totally subcutaneous implantable-cardioverter defibrillator. Circulation. 2013;128:944 53. S11.1-3. Lambiase PD, Barr C, Theuns DA, et al. Worldwide experience with a totally subcutaneous implantable defibrillator: early results from the EFFORTLESS S-ICD Registry. Eur Heart J. 2014;35:1657 65. S11.1-4. Burke MC, Gold MR, Knight BP, et al.


2014;35:1657 65. S11.1-4. Burke MC, Gold MR, Knight BP, et al. Safety and efficacy of the totally subcutaneous implantable defibrillator: 2-year results from a pooled analysis of the IDE study and EFFORTLESS registry. J Am Coll Cardiol. 2015;65:1605 15. S11.1-5. El-Chami MF, Levy M, Kelli HM, et al. Outcome of subcutaneous implantable cardioverter defibrillator implantation in patients with end-stage renal disease on dialysis. J Cardiovasc Electrophysiol. 2015;26:900 4. S11.1-6. de Bie MK, Thijssen J, van Rees JB, et al. Suitability for subcutaneous defibrillator implantation: results based on data from routine clinical practice. Heart. 2013;99:1018 23. S11.1-7. Olde Nordkamp LR, Dabiri AL, Boersma LV, et al. The entirely subcu- taneous implantable cardioverter-defibrillator: initial clinical experi- ence in a large Dutch cohort. J Am Coll Cardiol. 2012;60:1933 9. S11.1-8. K be J, Reinke F, Meyer C, et al. Implantation and follow-up of totally subcutaneous versus conventional implantable cardioverter- defibrillators: a multicenter case-control study. Heart Rhythm. 2013;10:29 36. S11.1-9. Groh CA, Sharma S, Pelchovitz DJ, et al. Use of an electrocar- diographic screening tool to determine candidacy for a subcu- taneous implantable cardioverter-defibrillator. Heart Rhythm. 2014;11:1361 6. S11.1-10. Olde Nordkamp LR, Warnaars JL, Kooiman KM, et al. Which patients are not suitable for a subcutaneous ICD: incidence and pre- dictors of failed QRS-T-wave morphology screening. J Cardiovasc Electrophysiol. 2014;25:494 9. S11.1-11. Randles DA, Hawkins NM, Shaw M, et al. How many patients fulfil the surface electrocardiogram criteria for subcutaneous implantable cardioverter-defibrillator implantation? Europace. 2014;16:1015 21. S11.1-12. Al-Khatib SM, Greiner MA, Peterson ED, et al. Patient and implant- ing physician factors associated with mortality and complications after implantable cardioverter-defibrillator implantation, 2002 2005. Circ Arrhythm Electrophysiol. 2008;1:240 9. S11.1-13. Olde Nordkamp LR, Knops RE, Bardy GH, et al.


S11.1-13. Olde Nordkamp LR, Knops RE, Bardy GH, et al. Rationale and design of the PRAETORIAN trial: a Prospective, RAndomizEd comparison of subcuTaneOus and tRansvenous ImplANtable cardioverter-defibrilla- tor therapy. Am Heart J. 2012;163:753 60. 11.2. Wearable Cardioverter-Defibrillator S11.2-1. Chung MK, The role of the wearable cardioverter defibrillator in clinical practice. Cardiol Clin. 2014;32:253 70. S11.2-2. Chung MK, Szymkiewicz SJ, Shao M, et al. Aggregate national experience with the wearable cardioverter-defibrillator: event rates, compliance, and survival. J Am Coll Cardiol. 2010;56:194 203. S11.2-3. Klein HU, Meltendorf U, Reek S, et al. Bridging a temporary high risk of sudden arrhythmic death. Experience with the wear- able cardioverter defibrillator (WCD). Pacing Clin Electrophysiol. 2010;33:353 67. S11.2-4. Piccini JP Sr, Allen LA, Kudenchuk PJ, et al. Wearable cardioverter- defibrillator therapy for the prevention of sudden cardiac death: a science advisory from the American Heart Association. Circulation. 2016;133:1715 27. S11.2-5. Ellenbogen KA, Koneru JN, Sharma PS, et al. Benefit of the wear- able cardioverter-defibrillator in protecting patients after implant- able-cardioverter defibrillator explant. Results from the National Registry. JACC Clin Electrophysiol. 2017;3:243 50. S11.2-6. LifeVest Wearable Cardioverter Defibrillator. Available at: http:// www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/ DeviceApprovalsandClearances/Recently-ApprovedDevices/ ucm458494.htm. Accessed August 26, 2016. 11.3. Automated External Defibrillator S11.3-1. Marenco JP, Wang PJ, Link MS, et al. Improving survival from sud- den cardiac arrest: the role of the automated external defibrillator. JAMA. 2001;285:1193 200. S11.3-2. Priori SG, Bossaert LL, Chamberlain DA, et al. ESC-ERC recommen- dations for the use of automated external defibrillators (AEDs) in Europe. Eur Heart J. 2004;25:437 5 S11.3-3. Blom MT, Beesems SG, Homma PC, et al. Improved survival after out-of-hospital cardiac arrest and use of automated external defi- brillators. Circulation. 2014;130:1868 75. S11.3-4. Koster RW, Automatic external defibrillator: key link in the chain of survival. J Cardiovasc Electrophysiol. 2002;13:S92 5. S11.3-5.


Koster RW, Automatic external defibrillator: key link in the chain of survival. J Cardiovasc Electrophysiol. 2002;13:S92 5. S11.3-5. Valenzuela TD, Roe DJ, Nichol G, et al. Outcomes of rapid defibrilla- tion by security officers after cardiac arrest in casinos. N Engl J Med. 2000;343:1206 9. S11.3-6. Caffrey SL, Willoughby PJ, Pepe PE, et al. Public use of automated external defibrillators. N Engl J Med. 2002;347:1242 7. S11.3-7. Page RL, Joglar JA, Kowal RC, et al. Use of automated external defi- brillators by a US airline. N Engl J Med. 2000;343:1210 6. S11.3-8. Page RL, Husain S, White LY, et al. Cardiac arrest at exercise facilities: implications for placement of automated external defibrillators. J Am Coll Cardiol. 2013;62:2102 9. S11.3-9. Weisfeldt ML, Sitlani CM, Ornato JP, et al. Survival after application of automatic external defibrillators before arrival of the emergency medical system: evaluation in the resuscitation outcomes consor- tium population of 21 million. J Am Coll Cardiol. 2010;55:1713 20. S11.3-10. Hansen CM, Lippert FK, Wissenberg M, et al. Temporal trends in coverage of historical cardiac arrests using a volunteer-based net- work of automated external defibrillators accessible to laypersons and emergency dispatch centers. Circulation. 2014;130:1859 67. S11.3-11. Weisfeldt ML, Everson-Stewart S, Sitlani C, et al. Ventricular tachyar- rhythmias after cardiac arrest in public versus at home. N Engl J Med. 2011;364:313 21. S11.3-12. Bardy GH, Lee KL, Mark DB, et al. Home use of automated external defibrillators for sudden cardiac arrest. N Engl J Med. 2008;358:1793 804. S11.3-13. Travers AH, Perkins GD, Berg RA, et al. Part 3: adult basic life sup- port and automated external defibrillation: 2015 International CLINICAL STATEMENTS AND GUIDELINES Consensus on Cardiopulmonary Resuscitation and Emergency Cardiovascular Care Science With Treatment Recommendations. Circulation. 2015;132:S51 83. 12. SPECIAL CONSIDERATIONS FOR CATHETER ABLATION S12-1.


Circulation. 2015;132:S51 83. 12. SPECIAL CONSIDERATIONS FOR CATHETER ABLATION S12-1. Blanck Z, Dhala A, Deshpande S, et al. Bundle branch reentrant ventricular tachycardia: cumulative experience in 48 patients. J Cardiovasc Electrophysiol. 1993;4:253 62. S12-2. Lopera G, Stevenson WG, Soejima K, et al. Identification and ablation of three types of ventricular tachycardia involving the his-purkinje system in patients with heart disease. J Cardiovasc Electrophysiol. 2004;15:52 8. S12-3. Mehdirad AA, Keim S, Rist K, et al. Long-term clinical outcome of right bundle branch radiofrequency catheter ablation for treatment of bundle branch reentrant ventricular tachycardia. Pacing Clin Electrophysiol. 1995;18:2135 43. S12-4. Dinov B, Fiedler L, Schonbauer R, et al. Outcomes in catheter abla- tion of ventricular tachycardia in dilated nonischemic cardiomy- opathy compared with ischemic cardiomyopathy: results from the Prospective Heart Centre of Leipzig VT (HELP-VT) study. Circulation. 2014;129:728 36. S12-5. Tanner H, Hindricks G, Volkmer M, et al. Catheter ablation of recurrent scar-related ventricular tachycardia using electroana- tomical mapping and irrigated ablation technology: results of the prospective multicenter Euro-VT-study. J Cardiovasc Electrophysiol. 2010;21:47 53. S12-6. Marchlinski FE, Haffajee CI, Beshai JF, et al. Long-term success of irrigated radiofrequency catheter ablation of sustained ventricu- lar tachycardia: post-approval THERMOCOOL VT trial. J Am Coll Cardiol. 2016;67:674 83. S12-7. Assomull RG, Prasad SK, Lyne J, et al. Cardiovascular magnetic reso- nance, fibrosis, and prognosis in dilated cardiomyopathy. J Am Coll Cardiol. 2006;48:1977 85. S12-8. Bogun FM, Desjardins B, Good E, et al. Delayed-enhanced mag- netic resonance imaging in nonischemic cardiomyopathy: utility for identifying the ventricular arrhythmia substrate. J Am Coll Cardiol. 2009;53:1138 45. S12-9. Roberts WC, Siegel RJ, McManus BM, Idiopathic dilated car- diomyopathy: analysis of 152 necropsy patients. Am J Cardiol. 1987;60:1340 55. S12-10. Piers SR, Tao Q, van Huls van Taxis C.F.B, et al.


Piers SR, Tao Q, van Huls van Taxis C.F.B, et al. Contrast-enhanced MRI-derived scar patterns and associated ventricular tachycardias in nonischemic cardiomyopathy: implications for the ablation strategy. Circ Arrhythm Electrophysiol. 2013;6:875 83. S12-11. Sacher F, Roberts-Thomson K, Maury P, et al. Epicardial ventricular tachycardia ablation a multicenter safety study. J Am Coll Cardiol. 2010;55:2366 72. S12-12. Della Bella P, Brugada J, Zeppenfeld K, et al. Epicardial ablation for ventricular tachycardia: a European multicenter study. Circ Arrhythm Electrophysiol. 2011;4:653 9. 13. POSTMORTEM EVALUATION OF SCD S13-1. Basso C, Burke M, Fornes P, et al. Guidelines for autopsy investiga- tion of sudden cardiac death. Virchows Arch. 2008;452:11 8. S13-2. de Noronha SV, Behr ER, Papadakis M, et al. The importance of specialist cardiac histopathological examination in the investigation of young sudden cardiac deaths. Europace. 2014;16:899 907. S13-3. Wilde AA, Behr ER. Genetic testing for inherited cardiac disease. Nature reviews. Cardiology. 2013;10:571 83. S13-4. Tester DJ, Medeiros-Domingo A, Will ML, et al. Cardiac channel molecular autopsy: insights from 173 consecutive cases of autopsy- negative sudden unexplained death referred for postmortem genetic testing. Mayo Clin. Proc. 2012;87:524 39. S13-5. Tang Y, Stahl-Herz J, Sampson BA. Molecular diagnostics of cardio- vascular diseases in sudden unexplained death. Cardiovasc Pathol. 2014;23:1 4. S13-6. Bagnall RD, Das KJ, Duflou J, et al. Exome analysis-based molecular autopsy in cases of sudden unexplained death in the young. Heart Rhythm. 2014;11:655 62. S13-7. Bagnall RD, Weintraub RG, Ingles J, et al. A prospective study of sudden cardiac death among children and young adults. N Engl J Med. 2016;374:2441 52. S13-8. Semsarian C, Ingles J. Molecular autopsy in victims of inherited arrhythmias. J Arrhythm. 2016;32:359 65. S13-9. Vassalini M, Verzeletti A, Restori M, et al. An autopsy study of sud- den cardiac death in persons aged 1 40 years in Brescia (Italy).


An autopsy study of sud- den cardiac death in persons aged 1 40 years in Brescia (Italy). J Cardiovasc Med. 2016;17:446 53. S13-10. Wu Q, Zhang L, Zheng J, et al. Forensic pathological study of 1656 cases of sudden cardiac death in southern. China Medicine. 2016;95:e2707. S13-11. Giudici V, Spanaki A, Hendry J, et al. Sudden arrhythmic death syndrome: diagnostic yield of comprehensive clinical evalua- tion of pediatric first-degree relatives. Pacing Clin Electrophysiol. 2014;37:1681 5. S13-12. Steinberg C, Padfield GJ, Champagne J, et al. Cardiac abnormali- ties in first-degree relatives of unexplained cardiac arrest victims: a report from the Cardiac Arrest Survivors With Preserved Ejection Fraction Registry. Circ Arrhythm Electrophysiol. 2016;9:e004274. S13-13. Wong LC, Roses-Noguer F, Till JA, et al. Cardiac evaluation of pedi- atric relatives in sudden arrhythmic death syndrome: a 2-center experience. Circ Arrhythm Electrophysiol. 2014;7:800 6. S13-14. van der Werf C, Stiekema L, Tan HL, et al. Low rate of cardiac events in first-degree relatives of diagnosis-negative young sudden unex- plained death syndrome victims during follow-up. Heart Rhythm. 2014;11:1728 32. S13-15. Papadakis M, Raju H, Behr ER, et al. Sudden cardiac death with autopsy findings of uncertain significance: potential for erroneous interpretation. Circ Arrhythm Electrophysiol. 2013;6:588 96. S13-16. Priori SG, Wilde AA, Horie M, et al. HRS/EHRA/APHRS expert con- sensus statement on the diagnosis and management of patients with inherited primary arrhythmia syndromes. Heart Rhythm. 2013;10:1932 63. 14. TERMINAL CARE S14-1. Berger JT, Gorski M, Cohen T. Advance health planning and treat- ment preferences among recipients of implantable cardioverter defibrillators: an exploratory study. J Clin Ethics. 2006;17:72 8. S14-2. Lewis KB, Stacey D, Matlock DD. Making decisions about implant- able cardioverter-defibrillators from implantation to end of life: an integrative review of patients perspectives. Patient. 2014;7:243 60. S14-3. Hill L, McIlfatrick S, Taylor B, et al.


2014;7:243 60. S14-3. Hill L, McIlfatrick S, Taylor B, et al. Patients perception of implant- able cardioverter defibrillator deactivation at the end of life. Palliat Med. 2015;29:310 23. S14-4. Hauptman PJ, Chibnall JT, Guild C, et al. Patient perceptions, physi- cian communication, and the implantable cardioverter-defibrillator. JAMA Intern Med. 2013;173:571 7. S14-5. Matlock DD, Nowels CT, Masoudi FA, et al. Patient and cardiolo- gist perceptions on decision making for implantable cardioverter- defibrillators: a qualitative study. Pacing Clin Electrophysiol. 2011;34:1634 4. S14-6. Buchhalter LC, Ottenberg AL, Webster TL, et al. Features and out- comes of patients who underwent cardiac device deactivation. JAMA Intern Med. 2014;174:80 5. S14-7. Dodson JA, Fried TR, Van Ness PH, et al. Patient preferences for deactivation of implantable cardioverter-defibrillators. JAMA Intern Med. 2013;173:377 9. S14-8. Goldstein NE, Lampert R, Bradley E, et al. Management of implant- able cardioverter defibrillators in end-of-life care. Ann Intern Med. 2004;141:835 8. S14-9. Goldstein N, Carlson M, Livote E, et al. Brief communication: man- agement of implantable cardioverter-defibrillators in hospice: a nationwide survey. Ann Intern Med. 2010;152:296 9. S14-10. Kirkpatrick JN, Gottlieb M, Sehgal P, et al. Deactivation of implant- able cardioverter defibrillators in terminal illness and end of life care. Am J Cardiol. 2012;109:91 4. S14-11. Kelley AS, Reid MC, Miller DH, et al. Implantable cardioverter-defi- brillator deactivation at the end of life: a physician survey. Am Heart J. 2009;157:702 8. CLINICAL STATEMENTS AND GUIDELINES S14-12. Kramer DB, Kesselheim AS, Brock DW, et al. Ethical and legal views of physicians regarding deactivation of cardiac implantable electrical devices: a quantitative assessment. Heart Rhythm. 2010;7:1537 42. S14-13. Mueller PS, Jenkins SM, Bramstedt KA, et al. Deactivating implanted cardiac devices in terminally ill patients: practices and attitudes. Pacing Clin Electrophysiol. 2008;31:560 8. 15. SHARED DECISION-MAKING S15-1. Lewis KB, Stacey D, Matlock DD.


15. SHARED DECISION-MAKING S15-1. Lewis KB, Stacey D, Matlock DD. Making decisions about implantable cardioverter-defibrillators from implantation to end of life: an integrative review of patients perspectives. Patient. 2014;7:243 60. S15-2. Stewart GC, Weintraub JR, Pratibhu PP, et al. Patient expectations from implantable defibrillators to prevent death in heart failure. J Card Fail. 2010;16:106 13. S15-3. Hauptman PJ, Chibnall JT, Guild C, et al. Patient perceptions, physi- cian communication, and the implantable cardioverter-defibrillator. JAMA Intern Med. 2013;173:571 7. S15-4. Ottenberg AL, Mueller PS, Topazian RJ, et al. It s not broke, so let s not try to fix it : why patients decline a cardiovascular implantable electronic device. Pacing Clin Electrophysiol. 2014;37:1306 14. S15-5. Yuhas J, Mattocks K, Gravelin L, et al. Patients attitudes and per- ceptions of implantable cardioverter-defibrillators: potential barri- ers to appropriate primary prophylaxis. Pacing Clin Electrophysiol. 2012;35:1179 87. S15-6. Vig EK, Pearlman RA. Good and bad dying from the perspective of terminally ill men. Arch Intern Med. 2004;164:977 81. S15-7. Charles C, Gafni A, Whelan T. Shared decision-making in the medical encounter: what does it mean? (or it takes at least two to tango). Soc Sci Med. 1997;44:681 92. S15-8. Quill TE, Brody H. Physician recommendations and patient auton- omy: finding a balance between physician power and patient choice. Ann Intern Med. 1996;125:763 9. 16. COST AND VALUE CONSIDERATIONS S16-1. Anderson JL, Heidenreich PA, Barnett PG, et al. ACC/AHA state- ment on cost/value methodology in clinical practice guidelines and performance measures: a report of the American College of Cardiology/American Heart Association Task Force on Performance Measures and Task Force on Practice Guidelines. Circulation. 2014;129:2329 45. S16-2. Sanders GD, Neumann PJ, Basu A, et al. Recommendations for conduct, methodological practices, and reporting of cost-effective- ness analyses: Second Panel on Cost-Effectiveness in Health and Medicine. JAMA. 2016;316:1093 103.


Recommendations for conduct, methodological practices, and reporting of cost-effective- ness analyses: Second Panel on Cost-Effectiveness in Health and Medicine. JAMA. 2016;316:1093 103. S16-3. Mushlin AI, Hall J, Zwanziger J, et al. The cost-effectiveness of automatic implantable cardiac defibrillators. Results from MADIT. Circulation. 1998;97:2129 35. S16-4. O Brien BJ, Connolly SJ, Goeree R, et al. Cost-effectiveness of the implantable cardioverter-defibrillator. Results from the Canadian Implantable Defibrillator Study (CIDS). Circulation. 2001;103:1416 21. S16-5. Larson G, Hallstrom A, McAnulty J, et al. Cost-effectiveness of the implantable cardioverter-defibrillator versus antiarrhythmic drugs in survivors of serious ventricular tachyarrhythmias. Results of the Antiarrhythmics Versus Implantable Defibrillators (AVID) Economic Analysis Substudy. Circulation. 2002;105:2049 57. S16-6. Zwanziger J, Hall WJ, Dick AW, et al. The cost-effectiveness of implantable cardioverter-defibrillators. Results from the Multicenter Automatic Defibrillator Implantation Trial (MADIT)-II. J Am Coll Cardiol. 2006;47:2310 8. S16-7. Mark DB, Nelson CL, Anstrom KJ, et al. Cost-effectiveness of defi- brillator therapy or amiodarone in chronic stable heart failure. Results from the Sudden Cardiac Death in Heart Failure Trial (SCD- HeFT). Circulation. 2006;114:135 42. S16-8. Weiss JP, Saynina O, McDonald KM, et al. Effectiveness and cost- effectiveness of implantable cardioverter defibrillators in the treat- ment of ventricular arrhythmias among Medicare beneficiaries. Am J Med. 2002;112:519 27. S16-9. Al-Khatib SM, Anstrom KJ, Eisenstein EL, et al. Clinical and eco- nomic implications of the Multicenter Automatic Defibrillator Implantation Trial-II. Ann Intern Med. 2005;142:593 600. S16-10. Buxton M, Caine N, Chase D, et al. A review of the evidence on the effects and costs of implantable cardioverter defibrillator therapy in different patient groups, and modelling of cost-effectiveness and cost-utility for these groups in a UK context. Health Technol Assess. 2006;10:iii iv, ix xi, 1 164. S16-11. Sanders GD, Hlatky MA, Owens DK. Cost effectiveness of implant- able cardioverter-defibrillators. N Engl J Med. 2005;353:1471 80. S16-12.


Cost effectiveness of implant- able cardioverter-defibrillators. N Engl J Med. 2005;353:1471 80. S16-12. Smith T, Jordaens L, Theuns D.A.M.J, et al. The cost-effectiveness of primary prophylactic implantable defibrillator therapy in patients with ischaemic or non-ischaemic heart disease: A European analysis. Eur Heart J. 2013;34:211 9. S16-13. Cowie MR, Marshall D, Drummond M, et al. Lifetime cost-effec- tiveness of prophylactic implantation of cardioverter defibril- lator in patients with reduced left ventricular systolic function: Results of Markov modelling in a European population. Europace. 2008;11:716 26. S16-14. Goldenberg I, Moss AJ, Maron BJ, et al. Cost-effectiveness of implanted defibrillators in young people with inherited cardiac arrhythmias. Ann Noninvasive Electrocardiol. 2005;10 suppl:67 83. S16-15. Bigger JT, Prophylactic use of implanted cardiac defibrillators in patients at high risk for ventricular arrhythmias after coronary-artery bypass graft surgery. N Engl J Med. 1997;337:1569 75. S16-16. Hohnloser SH, Kuck KH, Dorian P, et al. Prophylactic use of an implantable cardioverter-defibrillator after acute myocardial infarc- tion. N Engl J Med. 2004;351:2481 8. S16-17. Steinbeck G, Andresen D, Seidl K, et al. Defibrillator implantation early after myocardial infarction. N Engl J Med. 2009;361:1427 36. S16-18. Connolly SJ, Hallstrom AP, Cappato R, et al. Meta-analysis of the implantable cardioverter defibrillator secondary prevention trials. Eur Heart J. 2000;21:2071 8. S16-19. Owens DK, Sanders GD, Heidenreich PA, et al. Effect of risk stratifi- cation on cost-effectiveness of the implantable cardioverter defibril- lator. Am Heart J. 2002;144:440 8. S16-20. Ezekowitz JA, Rowe BH, Dryden DM, et al. Systematic review: implantable cardioverter defibrillators for adults with left ventricular systolic dysfunction. Ann Intern Med. 2007;147:251 62. 17. QUALITY OF LIFE S17-1. Mark DB, Anstrom KJ, Sun JL, et al. Quality of life with defibril- lator therapy or amiodarone in heart failure. N Engl J Med. 2008;359:999 1008. S17-2. Noyes K, Corona E, Veazie P, et al.


2008;359:999 1008. S17-2. Noyes K, Corona E, Veazie P, et al. Examination of the effect of implantable cardioverter-defibrillators on health-related quality of life: based on results from the Multicenter Automatic Defibrillator Trial-II. American journal of cardiovascular drugs: drugs, devices, and other interventions. 2009;9:393 400. S17-3. Passman R, Subacius H, Ruo B, et al. Implantable cardioverter defi- brillators and quality of life: results from the defibrillators in non- ischemic cardiomyopathy treatment evaluation study. Archives of internal medicine. 2007;167:2226 32. CLINICAL STATEMENTS AND GUIDELINES Appendix 1.


Archives of internal medicine. 2007;167:2226 32. CLINICAL STATEMENTS AND GUIDELINES Appendix 1. Author Relationships With Industry and Other Entities (Relevant) 2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death (October 2017) Committee Member Employment Consultant Speakers Bureau Ownership/ Partnership/ Principal Personal Research Institutional, Organizational, or Other Financial Benefit Expert Witness Voting Recusals by Section* Sana M. Al-Khatib, Chair Duke Clinical Research Institute; Duke University Professor of Medicine None None None None None None None William G. Stevenson, Vice Chair Vanderbilt University Medical Center Professor; Brigham and Women s Hospital Director of Clinical Cardiac EP St. Jude Medical Boston Scientific Biosense Webster Michael J. Ackerman Mayo Clinic Professor of Medicine, Pediatrics, and Pharmacology; Long QT Syndrome/Genetic Heart Rhythm Clinic and the Mayo Clinic Windland Smith Rice Sudden Death Genomics Laboratory Director Audentes Therapeutics Boston Scientific Gilead Sciences Invitae Medtronic MyoKardia St. Jude Medical None None None Transgenomic (Familion) Blue Ox Health Corporation AliveCor StemoniX William J. Bryant Dominick Feld Hyde Attorney at Law None None None None None None None David J. Callans University of Pennsylvania Health System Professor of Medicine; Associate Director of EP Biosense Webster Biotronik Boston Scientific Medtronic St. Jude Medical None None Biosense Webster (PI) Endosense (PI) Anne B. Curtis University at Buffalo SUNY Distinguished Professor; Charles and Mary Bauer Professor and Chair Medtronic St. Jude Medical Barbara J.


Author Relationships With Industry and Other Entities (Relevant) 2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death (October 2017) Committee Member Employment Consultant Speakers Bureau Ownership/ Partnership/ Principal Personal Research Institutional, Organizational, or Other Financial Benefit Expert Witness Voting Recusals by Section* Sana M. Al-Khatib, Chair Duke Clinical Research Institute; Duke University Professor of Medicine None None None None None None None William G. Stevenson, Vice Chair Vanderbilt University Medical Center Professor; Brigham and Women s Hospital Director of Clinical Cardiac EP St. Jude Medical Boston Scientific Biosense Webster Michael J. Ackerman Mayo Clinic Professor of Medicine, Pediatrics, and Pharmacology; Long QT Syndrome/Genetic Heart Rhythm Clinic and the Mayo Clinic Windland Smith Rice Sudden Death Genomics Laboratory Director Audentes Therapeutics Boston Scientific Gilead Sciences Invitae Medtronic MyoKardia St. Jude Medical None None None Transgenomic (Familion) Blue Ox Health Corporation AliveCor StemoniX William J. Bryant Dominick Feld Hyde Attorney at Law None None None None None None None David J. Callans University of Pennsylvania Health System Professor of Medicine; Associate Director of EP Biosense Webster Biotronik Boston Scientific Medtronic St. Jude Medical None None Biosense Webster (PI) Endosense (PI) Anne B. Curtis University at Buffalo SUNY Distinguished Professor; Charles and Mary Bauer Professor and Chair Medtronic St. Jude Medical Barbara J. Deal Getz Professor of Cardiology Feinberg School of Medicine Northwestern University None None None None None None None Timm Dickfeld University of Maryland Associate Professor of Medicine Biosense St. Jude Medical Siemens None None Biosense General Electric Impulse Dynamics Siemens Anne M. Gillis University of Calgary Professor of Medicine None None None Christopher B. Granger Duke Clinical Research Institute; Duke University Professor of Medicine; Director, Cardiac Care Unit AstraZeneca Gilead Sciences GlaxoSmithKline Janssen Pharmaceuticals Medtronic Pfizer Sanofi-aventis None None AstraZeneca GlaxoSmithKline Janssen Pharmaceuticals Medtronic Pfizer Sanofi-aventis GE Healthcare Medtronic ZOLL Medical Spacelabs Phillips Stephen C. Hammill Mayo Clinic Professor Emeritus of Medicine None None None None None None None Mark A. Hlatky Stanford University School of Medicine Professor of Health and Research Policy, and of Cardiovascular Medicine None None None None None None None Jos A. Joglar UT Southwestern Medical Center Professor of Internal Medicine; Clinical Cardiac EP Fellowship Program Director None None None None None None None G. Neal Kay University of Alabama at Birmingham Professor Emeritus None None None None None None None Michael E. Field University of Wisconsin School of Medicine and Public Health Director, Clinical EP and Cardiac Arrhythmia Service, Associate Professor of Medicine None None None None None None None (Continued) CLINICAL STATEMENTS AND GUIDELINES Gregg C. Fonarow Ahmanson-UCLA Cardiomyopathy Center Director; UCLA Division of Cardiology Co-Chief Amgen Janssen Pharmaceuticals Medtronic ZS Pharma None None Medtronic IMPROVE-HF (Steering Committee) Medtronic Daniel D. Matlock University of Colorado School of Medicine Associate Professor of Medicine None None None None None None None Robert J. Myerburg University of Miami Miller School of Medicine Professor of Medicine and Physiology None None None None None None None Richard L. Page University of Wisconsin Hospital and Clinics Chair, Department of Medicine None None None None None None None This table represents the relationships of committee members with industry and other entities that were determined to be relevant to this document.


These relationships were reviewed and updated in conjunction with all meetings and/or conference calls of the writing committee during the document development process. The table does not necessarily reflect relationships with industry at the time of publication. A person is deemed to have a significant interest in a business if the interest represents ownership of 5% of the voting stock or share of the business entity, or ownership of $5,000 of the fair market value of the business entity; or if funds received by the person from the business entity exceed 5% of the person s gross income for the previous year. Relationships that exist with no financial benefit are also included for the purpose of transparency. Relationships in this table are modest unless otherwise noted. According to the ACC/AHA, a person has a relevant relationship IF: a) the relationship or interest relates to the same or similar subject matter, intellectual property or asset, topic, or issue addressed in the document; or b) the company/entity (with whom the relationship exists) makes a drug, drug class, or device addressed in the document, or makes a competing drug or device addressed in the document; or c) the person or a member of the person s household, has a reasonable potential for financial, professional or other personal gain or loss as a result of the issues/content addressed in the document. *Writing committee members are required to recuse themselves from voting on sections to which their specific relationships with industry and other entities may apply. Significant relationship. No financial benefit. ACC indicates American College of Cardiology; AHA, American Heart Association; EP, Electrophysiology; HRS, Heart Rhythm Society; IMPROVE-HF, Improve the Use of Evidence-Based Heart Failure Therapies in the Outpatient Setting; PI, principal investigator; SUNY, State University of New York; and UT, University of Texas.